{ "schemaVersion": "deck-intelligence.v1", "id": "019de075-c130-77ea-b60f-b21955e0fc8e", "slug": "71c1598fd07d494c4a73d86584bdcfa9", "title": "Nuvalent | Investor Presentation Deck | 39 slides", "subtitle": "Nuvalent · 2023-08", "author": "Nuvalent", "date": "2023-08-01 00:00:00", "pageCount": 39, "kind": "pitchdeck", "orientation": "landscape", "aspectRatio": 1.7777778, "document": { "id": "019de075-c130-77ea-b60f-b21955e0fc8e", "slug": "71c1598fd07d494c4a73d86584bdcfa9", "title": "Nuvalent | Investor Presentation Deck | 39 slides", "rawTitle": "Nuvalent | Investor Presentation Deck | 39 slides", "authorId": "nuvalent", "authorName": "Nuvalent", "authorDisplay": "Nuvalent", "kind": { "slug": "pitchdeck", "label": "Pitch deck" }, "sourceType": { "slug": "investor_relations", "label": "Investor relations" }, "fileName": "2023-08__nuvalent__investor-pres__71c1598f.pdf", "sourceUrl": "https://www.slidebook.io/company/nuvalent/presentation/71c1598fd07d494c4a73d86584bdcfa9/", "sourceDate": "2023-08-10 00:00:00", "presentationDate": "2023-08-01 00:00:00", "ingestedAt": "2026-04-30 22:15:06.902295+00", "status": "ready", "pageCount": 39, "orientation": "landscape", "aspectRatio": 1.7777778, "targetCompany": null, "targetTicker": null, "metadata": { "corpus": "slidebook", "industry": "biotechnology", "local_root": "/Users/miguelsuredasuau/Desktop/lalalalla/_scrape/slidebook/decks/2023-08__nuvalent__investor-pres__71c1598f", "image_width": 1920, "image_format": "jpg", "deck_type_raw": "Investor Presentation Deck", "deck_type_slug": null, "source_url_pattern": "https://www.slidebook.io/company/{company_slug}/presentation/{deck_id}/" } }, "coverage": { "pageCount": 39, "pagesIndexed": 39, "pagesWithImages": 39, "pagesWithMetadata": 39, "imageCoveragePct": 100, "metadataCoveragePct": 100, "componentCount": 187, "chartCount": 18, "metricSlides": 0, "toolMatches": 24, "documentToolMatches": 0, "frameworkMatches": 8, "arcMatches": 1, "beatMatches": 5, "loopMatches": 3, "patternMatches": 0, "storymakersMatch": false, "scoreAvailable": false, "reviewAvailable": false, "activistThesisAvailable": false, "pitchdeckMetadataAvailable": false, "pitchdeckProfileAvailable": false }, "blocks": [], "matches": { "arcs": [ { "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "matchId": "94029b68-a5c1-4a28-8d68-beb9720b9a6d", "evidence": "The deck follows a structure similar to the Sequoia Pitch, with sections on problem, solution, market sizing, competitive analysis, and traction.", "isPrimary": true, "confidence": 0.8, "extraction": { "at": "2026-07-16 22:37:21.512586+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "beats": [ { "to": 7, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 7, "name": "Problem", "beatId": "b7fbf414-8df7-4ba0-a8a4-eda6bab91c20", "matchId": "94029b68-a5c1-4a28-8d68-beb9720b9a6d", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "The problem of kinase resistance is clearly stated.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 6, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 6, "name": "Solution", "beatId": "af08a215-8bda-49a9-b4de-9eba972cf7ae", "matchId": "94029b68-a5c1-4a28-8d68-beb9720b9a6d", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "The solution of precisely targeted therapies is introduced.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 10, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 10, "name": "Market Sizing", "beatId": "4cedff80-36c0-4bbc-a462-ced06248d8ee", "matchId": "94029b68-a5c1-4a28-8d68-beb9720b9a6d", "beatType": null, "evidence": "The market for ROS1-positive NSCLC is sized.", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 24, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 19, "name": "Traction", "beatId": "fe8c99d1-59ae-4350-9a12-ffd07cd22e0a", "matchId": "94029b68-a5c1-4a28-8d68-beb9720b9a6d", "beatType": null, "evidence": "Preliminary efficacy and safety data are presented.", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 11, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 11, "name": "Competitive Analysis", "beatId": "7a498776-5a16-472f-bc57-dc9a095453a4", "matchId": "94029b68-a5c1-4a28-8d68-beb9720b9a6d", "beatType": { "name": "Competition", "slug": "sequoia-pitch-competition", "status": "active", "canonId": "019dd9b8-21bd-7407-8707-bdf217ed9c76", "version": 1, "description": null }, "evidence": "NVL-520 is compared to existing treatments.", "position": 4, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 12, "from": 7, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null, "categoryName": "Urgency", "categorySlug": "urgency" }, "matchId": "781a9db6-60df-4e5f-9ef7-9eb3f3b812ae", "evidence": "The limitations of current treatments are discussed.", "position": 0, "objective": "What are the consequences of not addressing kinase resistance?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:37:21.755678+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 24, "from": 19, "loop": { "name": "14_day_in_life", "slug": "14-day-in-life", "status": "active", "bestFor": "Product demos, UX reviews, investor pitches focusing on pain points", "canonId": "019dd956-6b65-707f-9b14-89beaaab81fa", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The User's Struggle -> The Intervention (Your Solution) -> The Resolved State", "description": "Humanize abstract data by walking through a single user's struggle and resolution", "familyLabel": null, "categoryName": "Narrative", "categorySlug": "narrative" }, "matchId": "a5849bfd-1f57-46db-8128-2b35af72eb66", "evidence": "Preliminary efficacy data are presented.", "position": 1, "objective": "How do patients benefit from Nuvalent's therapies?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:37:21.795555+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 9, "from": 6, "loop": { "name": "53_jobs_to_be_done", "slug": "53-jobs-to-be-done", "status": "active", "bestFor": "Product innovation, market entry, competitive positioning", "canonId": "019dd956-7b6c-7594-b5b3-eecbe0ab48e8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying", "familyLabel": null, "categoryName": "Consulting Framework", "categorySlug": "consulting-framework" }, "matchId": "7d073297-3453-4a5f-a314-d600119c06ad", "evidence": "The need for precisely targeted therapies is discussed.", "position": 2, "objective": "What are the unmet needs in cancer treatment?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:37:21.835621+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "tools": [ { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "0279f65c-5a52-43f8-88a1-6a0fcc7786b9", "evidence": "list/bullet: Trial initiated for parallel lead program: ALKOVE-1 Phase 1/2 study of NVL-655 for patients with advanced ALK-positive NSCLC and other solid tumors, with update on preliminary dose-escalation data expected a", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:31:08.920935+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 4, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "1a85b6f6-b80c-43c0-9743-184da1d81b73", "evidence": "list/bullet: Board of Directors and Scientific Advisors lists", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:31:09.003256+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Venn diagram", "slug": "venn-diagram", "status": "active", "bestFor": null, "canonId": "019de52d-1f53-7290-96c8-79388c95fc17", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "d0b5c8ee-2541-4993-8b7c-4817b07c0702", "evidence": "diagram/venn: Venn diagram showing the intersection of Kinase Resistance and Kinase Selectivity", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:31:09.08409+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Problem Statement Canvas", "slug": "problem-statement-canvas", "status": "active", "bestFor": null, "canonId": "019dd956-839d-744b-ad11-9bf3e3642a18", "version": 1, "bodyDocId": null, "description": "Structured definition of the problem: What? Who? Where? When? Scale?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "8860dd90-b7f8-45a3-ad71-6efd107a127b", "evidence": "Structural innovations designed to overcome drug-resistance due to kinase mutations", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:31:02.951991+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "8572f4a5-321f-41cd-9e56-4dedeec4905c", "evidence": "Active against treatment-emergent ROS1 resistance mutations: G2032R, D2033N, L2026M, S1986Y/F", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:31:03.074016+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Market Segmentation Pyramid", "slug": "market-segmentation-pyramid", "status": "active", "bestFor": null, "canonId": "1c9f3543-c96f-4a5b-b4a4-9b2a412c0aaf", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "c2e9a912-1259-437b-9377-64b47b091262", "evidence": "ROS1-positive NSCLC Market Overview", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:31:03.155994+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "4b69bf1d-4070-4662-b161-e96c9c0e96e7", "evidence": "Line of Therapy, Sub-population, Incidence (US), CNS Disease, Standard of Care (2022)", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:31:03.196994+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "2x2 matrix", "slug": "matrix-2x2", "status": "active", "bestFor": null, "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8", "version": 1, "bodyDocId": null, "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "2303063c-957d-43f3-80e4-064143ab5743", "evidence": "Comparison matrix of NVL-520 vs Crizotinib, Entrectinib, Lorlatinib, and Repotrectinib across 4 activity categories.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:31:03.279032+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 11, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Problem-Agitate-Solve (PAS)", "slug": "problem-agitate-solve-pas", "status": "active", "bestFor": null, "canonId": "019dd956-869f-7564-8d42-de54ed29ab90", "version": 1, "bodyDocId": null, "description": "Identify problem, agitate the pain, present the solution", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "50a1cd82-c556-4b6d-8774-4fc350cdbd2e", "evidence": "ROS1 and ALK both share strong structural similarities to TRK.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.6, "extraction": { "at": "2026-07-17 00:31:03.362606+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "b2423d13-7dd4-4e25-b72f-e773be805b3a", "evidence": "In vivo efficacy tumor regression bar chart", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.6, "extraction": { "at": "2026-07-17 00:31:03.446295+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "2a5c414b-b7ff-46ef-a111-72d2f3040a0f", "evidence": "Patient characteristics and treatment history table", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:31:03.654721+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 17, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "5c15b005-3fc5-48e0-8459-3f1f03d48bd6", "evidence": "chart/line: Pharmacokinetic concentration over time chart", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:31:02.624807+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 19, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "763b8443-acb9-467b-9ee8-c0d325ed661a", "evidence": "chart/waterfall: Waterfall plot of best percentage change in target lesions", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:31:02.722736+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 21, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Sparklines (Chart)", "slug": "sparklines-chart", "status": "active", "bestFor": null, "canonId": "019dd956-b3db-7239-aa95-d24b7cdc29e4", "version": 1, "bodyDocId": null, "description": "Word-sized graphics embedded in text for data density", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "29000ee1-a04f-4dcc-92cf-a8121c6957e0", "evidence": "chart/bar-horizontal: Swimmer plot of treatment duration by patient", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:31:02.788974+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 22, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "2x2 matrix", "slug": "matrix-2x2", "status": "active", "bestFor": null, "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8", "version": 1, "bodyDocId": null, "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "72ae47d2-6e30-4886-abcc-72ad7bc60efd", "evidence": "table/data: Dose level and prior therapy history table", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:31:02.853941+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 23, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "NxN matrix", "slug": "matrix-nxn", "status": "active", "bestFor": null, "canonId": "019de52d-2313-71fa-bb45-a7d1a4aae23a", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "c8a6a78f-3a24-448c-8530-e748747e6e8c", "evidence": "table/data: Comparison matrix of NVL-655 vs Crizotinib, Ceritinib, Alectinib, Brigatinib, Lorlatinib across 5 activity categories", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:31:03.073769+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 29, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Chartjunk Elimination", "slug": "chartjunk-elimination", "status": "active", "bestFor": null, "canonId": "019dd956-b49e-7453-ab01-b60f338eeda1", "version": 1, "bodyDocId": null, "description": "Remove decorative elements that don't convey data: 3D effects, shadows, unnecessary gridlines", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "d7c7427f-9761-4199-a1d4-53563230db2f", "evidence": "chart/line: In vivo activity, patient-derived xenograft (PDX) ALK+ NSCLC with G1202R/L1196M compound mutation", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:31:16.341949+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 31, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "636c3723-63f1-46a5-a24a-078a3ba524b6", "evidence": "table/data: Phase 1 and Phase 2 cohort definitions including tumor type, prior ALK TKI, and prior chemo/IO lines.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:31:16.421926+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 32, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "afa0a69f-5771-4550-9bfc-20d26e12455a", "evidence": "list/bullet: Brain penetrant. ~20% of patients with HER2-positive NSCLC present with brain metastases", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:31:16.503242+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 33, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "862fe5bb-cfec-4ff1-917a-75f5fe2aa618", "evidence": "chart/dot: IN VITRO ACTIVITY, HER2 AND HER2ex20", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:31:16.585296+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 34, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Section divider", "slug": "section-divider", "status": "active", "bestFor": null, "canonId": "019dd9e1-4c66-707d-8d1f-6e14547134c7", "version": 1, "bodyDocId": null, "description": "A transitional slide marking the start of a new section.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "da8f0b11-61df-4422-bf3f-63a6e16bc192", "evidence": "title/headline: Pipeline Expansion", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:31:16.668071+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 35, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Process flow", "slug": "process-flow", "status": "active", "bestFor": null, "canonId": "019dd9e1-4dca-76bc-8135-401836a1c4c0", "version": 1, "bodyDocId": null, "description": "Workflow, steps, sequential diagram.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "530f04d4-45df-42b8-b276-222195d06058", "evidence": "diagram/process: Three-step process flow using hexagonal icons", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:31:16.757389+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 36, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "72124841-56e3-4996-9661-bdcfd5900ab5", "evidence": "paragraph/paragraph: Robust development pipeline leveraging established approach: NVL-330 selected as new development candidate for HER2ex20-positive tumors", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:31:16.879035+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 38, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "4dac34b4-0e3d-40b2-9004-b8bc4a443da7", "evidence": "title/action-title: PRECISELY Targeted Therapies for patients with cancer", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:31:16.960182+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 39, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "d8c55ff4-f93f-4877-bd46-c69d1cf53245", "evidence": "Visual intersection of two concepts", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:33:55.433+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "frameworkName": "venn" }, { "matchId": "ad7de20c-240b-47ba-8f3b-dfc1a523ee71", "evidence": "Contrasts the state of existing therapy failure with the solution provided by Nuvalent.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:33:56.169+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "frameworkName": "before-after-bridge" }, { "matchId": "9c4594c3-3e95-4b02-a927-ec2546eb8c71", "evidence": "Side-by-side visual comparison of non-selective vs selective therapy", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:33:56.714+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "frameworkName": "comparison-frame" }, { "matchId": "74e5d306-f6f2-40eb-8437-b8542677fbbe", "evidence": "Segments market by line of therapy and mutation status", "framework": null, "confidence": 0.7, "extraction": { "at": "2026-05-02 11:34:00.302+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "frameworkName": "market-segmentation-pyramid" }, { "matchId": "aa70cc1c-3596-4f37-a670-77408dd3edf3", "evidence": "Table comparing product features against competitors", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:33:58.509+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 11, "frameworkName": "comparison_frame" }, { "matchId": "f0c8731e-a666-42e2-b4f6-eca59f65b937", "evidence": "Table comparing product features against competitors", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:33:59.66+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 29, "frameworkName": "comparison-frame" }, { "matchId": "fd200d40-7050-4b6b-9e63-480796e4e920", "evidence": "Sequential flow of three strategic steps", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:34:01.125+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 36, "frameworkName": "process" }, { "matchId": "4f47e245-8219-4fd6-9590-7fc6d03b6a9e", "evidence": "The slide uses a horizontal bar structure to represent progress through clinical phases.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:34:00.792+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 37, "frameworkName": "gantt-chart" } ], "patterns": [] }, "storymakers": null, "score": null, "review": null, "activistThesis": null, "pitchdeck": { "metadata": null, "profile": null }, "slides": [ { "page": 1, "type": "setup", "title": "Features company logo, date, and a molecular structure visualization.", "function": "front_matter", "imagePath": "https://imgproxy.kitesheet.com/sh_0wuvStZQltsGU67hP1V5Aytw_MSAb5RHl9N6j3QQ/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy83MWMxNTk4ZmQwN2Q0OTRjNGE3M2Q4NjU4NGJkY2ZhOS9wMDAxLmpwZw", "rawType": "cover", "block": null, "metadata": { "slideType": "cover", "slideTypeCanon": { "name": "Cover", "slug": "cover", "status": "active", "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "balanced", "densityScore": 29, "componentCount": 5, "textChars": 94, "nDataPoints": 0, "notes": "Features company logo, date, and a molecular structure visualization.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:33:54.661+00", "seconds": 2.591, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/1", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-1", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.35, "x": 0.3, "y": 0.85 }, "kind": "callout", "text": "PRECISELY Targeted Therapies for patients with cancer", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:54.661+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1625d843-f001-43bf-b525-b06e01b07954", "parentComponentId": null }, { "bbox": { "h": 0.9, "w": 0.4, "x": 0.55, "y": 0.05 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:54.661+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2a32f116-66cb-47a4-9efd-7ae983cf3319", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.3, "x": 0.05, "y": 0.15 }, "kind": "image", "text": "Nuvalent", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:54.661+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1b5563d6-906e-407f-aebe-1a4688e0b61c", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.2, "x": 0.05, "y": 0.6 }, "kind": "paragraph", "text": "August 10, 2023", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:54.661+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4d0518a9-909f-43d4-9a9b-730cb91f44df", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.4, "x": 0.05, "y": 0.45 }, "kind": "title", "text": "Corporate Overview", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:54.661+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3a02f165-7db4-4ed5-976e-3f76601b1860", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "thumbSrc": "https://imgproxy.kitesheet.com/pp4Z7eEpoMGDbGe595flUjNXJtyvzCXtjtyfFcAls2I/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy83MWMxNTk4ZmQwN2Q0OTRjNGE3M2Q4NjU4NGJkY2ZhOS9wMDAxLmpwZw", "imagePathAlt": "https://imgproxy.kitesheet.com/NsgE5a6jqM6EyKOyQhcqee_4cIWnQIxBHgfOBDoiHSY/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy83MWMxNTk4ZmQwN2Q0OTRjNGE3M2Q4NjU4NGJkY2ZhOS9wMDAxLnBuZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/_kS6HCH_NwHE8regRfhEHeNx6KSUdVIXgwcIWLJcWZk/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy83MWMxNTk4ZmQwN2Q0OTRjNGE3M2Q4NjU4NGJkY2ZhOS9wMDAxLnBuZw" }, { "page": 2, "type": "setup", "function": "other", "rawType": "appendix_disclosure", "block": null, "metadata": { "slideType": "appendix_disclosure", "slideTypeCanon": { "name": "Appendix disclosure", "slug": "appendix_disclosure", "status": "active", "canonId": "019de52d-07b2-7549-8e8b-932a19f6e616", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "balanced", "densityScore": 36, "componentCount": 3, "textChars": 522, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:33:55.168+00", "seconds": 2.848, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/2", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-2", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.315, "w": 0.846, "x": 0.077, "y": 0.233 }, "kind": "disclaimer", "text": "This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995... You should not place undue reliance on these statements or the scientific data presented.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:55.168+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "03621c60-7541-4f8e-a87a-eb6531a02972", "parentComponentId": null }, { "bbox": { "h": 0.355, "w": 0.846, "x": 0.077, "y": 0.551 }, "kind": "disclaimer", "text": "Any forward-looking statements in this presentation are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties, and important factors that may cause actual events or results to differ materially...", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:55.168+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8f813382-ffe1-474c-a8bf-507a60965d6d", "parentComponentId": null }, { "bbox": { "h": 0.033, "w": 0.712, "x": 0.077, "y": 0.135 }, "kind": "title", "text": "CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:55.168+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c17c5650-38e9-44f9-8a55-4b5130d309ca", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 3, "type": "setup", "title": "The slide uses a visual bracket system to connect the three pillars to the core mission statement.", "function": "inspire_vision", "rawType": "mission", "block": null, "metadata": { "slideType": "mission", "slideTypeCanon": { "name": "Mission", "slug": "mission", "status": "active", "canonId": "019de52d-0fce-7496-b34c-18fd6a6e3310", "version": 1, "description": null }, "function": "inspire_vision", "functionCanon": { "name": "Inspire vision", "slug": "inspire_vision", "status": "active", "canonId": "019de52d-16d0-7756-83de-376eeac6fa40", "version": 1, "description": null }, "density": "balanced", "densityScore": 40, "componentCount": 4, "textChars": 433, "nDataPoints": 0, "notes": "The slide uses a visual bracket system to connect the three pillars to the core mission statement.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 15:31:03.612+00", "seconds": 5.74, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/3", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-3", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "x": 0.65, "y": 525 }, "kind": "list", "text": "Driven by Purpose: Precisely designed solutions aiming to overcome limitations of existing therapies identified through close collaboration with physician-scientists", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 15:31:03.612+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0b2c53ad-6525-4da6-bdfb-13652a777862", "parentComponentId": null }, { "bbox": { "x": 0.08, "y": 525 }, "kind": "list", "text": "Chemistry at the core: Expertise in chemistry and structure-based drug design drives wholly-owned pipeline of novel targeted therapies", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 15:31:03.612+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "72faff52-aa62-490d-9855-00e510927107", "parentComponentId": null }, { "bbox": { "x": 0.38, "y": 525 }, "kind": "list", "text": "Built for Patients: Our mission is to bring new medicines to patients with cancer", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 15:31:03.612+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "968d67f1-3ff8-405a-92c3-5c550e6778dd", "parentComponentId": null }, { "bbox": { "x": 0.08, "y": 0.19 }, "kind": "title", "text": "PRECISELY Targeted Therapies for patients with cancer", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 15:31:03.612+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "afe6f1f0-846b-4b7d-aab0-2b2d67910889", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 4, "type": "evidence", "title": "The slide combines a retrospective traction report with a mission/vision statement.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 89, "componentCount": 10, "textChars": 884, "nDataPoints": 2, "notes": "The slide combines a retrospective traction report with a mission/vision statement.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:33:56.66+00", "seconds": 3.914, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/4", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-4", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.4, "x": 0.06, "y": 0.68 }, "kind": "list", "text": "Continued advancement of internal research & discovery pipeline", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:56.66+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2557ff69-21a4-4f6e-b956-e5b482ae9f3f", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.4, "x": 0.06, "y": 0.84 }, "kind": "list", "text": "$264.5M upsized financing expected to extend cash runway into 2nd half of 2025", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:56.66+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3b55b0a4-987f-4816-9da6-c08752a66848", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.4, "x": 0.06, "y": 0.76 }, "kind": "list", "text": "Continued team growth (60+ FTEs)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:56.66+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3c9c2fb5-8673-4bf9-adca-7ae214d68c52", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.4, "x": 0.06, "y": 0.6 }, "kind": "list", "text": "Nominated 3rd development candidate: NVL-330, a HER2ex20-selective inhibitor", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:56.66+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b30e5e99-57ab-4ae0-af51-e231ca5de650", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.4, "x": 0.06, "y": 0.42 }, "kind": "list", "text": "Trial initiated for parallel lead program: ALKOVE-1 Phase 1/2 study of NVL-655 for patients with advanced ALK-positive NSCLC and other solid tumors, with update on preliminary dose-escalation data expected at a medical meeting in 4Q'23", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:56.66+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bd623a2b-b23e-4c98-848d-347857cd8f15", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.4, "x": 0.06, "y": 0.28 }, "kind": "list", "text": "Preliminary Phase 1 data presented at EORTC-NCI-AACR: ARROS-1 Phase 1/2 study of NVL-520 for patients with advanced ROS1-positive NSCLC and other solid tumors", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:56.66+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "edb0b9d3-34ca-48da-9a4d-a9c1b1b40c02", "parentComponentId": null }, { "bbox": { "h": 0.09, "w": 0.335, "x": 0.615, "y": 0.498 }, "kind": "paragraph", "text": "Fully integrated pharmaceutical company with the goal of translating deep expertise in chemistry & structure-based drug design into best-in-class small molecule medicines for patients with cancer", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:56.66+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "60d8b639-eb35-495e-b61a-61755391e832", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.27, "x": 0.648, "y": 0.395 }, "kind": "paragraph", "text": "Discover, Develop & Deliver", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:56.66+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "72ed63b5-90db-479f-88b0-5e2e1c2ad7a0", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.1, "x": 0.733, "y": 0.318 }, "kind": "title", "text": "Vision", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:56.66+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "40b59d87-7b36-4511-a8d7-e68bce78ee07", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.18, "x": 0.06, "y": 0.1 }, "kind": "title", "text": "2022 IN REVIEW", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:56.66+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c3ab2882-a1a0-4407-8ab2-c184e0985fe9", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "0279f65c-5a52-43f8-88a1-6a0fcc7786b9", "evidence": "list/bullet: Trial initiated for parallel lead program: ALKOVE-1 Phase 1/2 study of NVL-655 for patients with advanced ALK-positive NSCLC and other solid tumors, with update on preliminary dose-escalation data expected a", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:31:08.920935+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 4, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 5, "type": "setup", "title": "Includes a grid of headshots for the leadership team and lists for board members and advisors, plus a logo-grid for prior FDA approvals.", "function": "other", "rawType": "team_bio", "block": null, "metadata": { "slideType": "team_bio", "slideTypeCanon": { "name": "Team bio", "slug": "team_bio", "status": "active", "canonId": "019de52d-0a7d-7394-ae5b-037478e71f1e", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "balanced", "densityScore": 36, "componentCount": 5, "textChars": 199, "nDataPoints": 0, "notes": "Includes a grid of headshots for the leadership team and lists for board members and advisors, plus a logo-grid for prior FDA approvals.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:33:55.861+00", "seconds": 3.002, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/5", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-5", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.55, "w": 0.56, "x": 0.07, "y": 0.28 }, "kind": "image", "text": "Leadership team headshots", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:55.861+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8a22c9e9-455d-4bd9-9d24-9e8bf04d027d", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.37, "x": 0.19, "y": 0.83 }, "kind": "image", "text": "Prior FDA approval experience logos", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo grid", "slug": "logo-grid", "status": "active", "canonId": "019de52c-fdd7-7409-93e5-81280a8ca215", "version": 1, "description": null }, "framework": null }, "subkind": "logo-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:55.861+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8419452e-41cf-4ba5-83ce-001b1867118e", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.3, "x": 0.67, "y": 0.25 }, "kind": "list", "text": "Board of Directors and Scientific Advisors lists", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:55.861+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f8bf6309-1a0e-406a-a9da-6a487b279a8a", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.63, "x": 0.07, "y": 0.18 }, "kind": "title", "text": "Significant Experience in Drug Discovery, Development and Company Building", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:55.861+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a5163f2b-4882-4cf5-beab-71b28bb68548", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.33, "x": 0.07, "y": 0.11 }, "kind": "title", "text": "The Nuvalent Team", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:55.861+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fe6ea18c-4c2c-4e4e-98c2-ae98bd983e73", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "1a85b6f6-b80c-43c0-9743-184da1d81b73", "evidence": "list/bullet: Board of Directors and Scientific Advisors lists", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:31:09.003256+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 6, "type": "resolution", "title": "Uses a Venn diagram to illustrate the intersection of Kinase Resistance and Kinase Selectivity.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 46, "componentCount": 4, "textChars": 573, "nDataPoints": 0, "notes": "Uses a Venn diagram to illustrate the intersection of Kinase Resistance and Kinase Selectivity.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:33:55.433+00", "seconds": 2.562, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/6", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-6", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.8, "w": 0.45, "x": 0.5, "y": 0.1 }, "kind": "diagram", "text": "Venn diagram showing the intersection of Kinase Resistance and Kinase Selectivity", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Venn diagram", "slug": "venn", "status": "active", "canonId": "019de52d-0463-710d-b529-cce18d828d2f", "version": 1, "description": null }, "framework": null }, "subkind": "venn", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:55.433+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4f630eae-266a-438a-95e0-616fb1ce7107", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.4, "x": 0.07, "y": 0.55 }, "kind": "list", "text": "Expertise in structure-based drug design to create innovative small molecules. \"Threading the needle\": Aim to achieve high affinity for drug-resistant kinases while avoiding off-target kinases. Potential to minimize adverse events AND drive more durable responses", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:55.433+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6395588c-ad8d-46d0-9c1c-cedf96843fe3", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.4, "x": 0.07, "y": 0.35 }, "kind": "paragraph", "text": "Nuvalent is focused on creating precisely targeted therapies to overcome key limitations of existing therapies for clinically proven kinases and renew hope for patients in need", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:55.433+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f256f156-b4bd-45ef-8f46-ffe10f0c24ea", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.4, "x": 0.07, "y": 0.12 }, "kind": "title", "text": "PRECISELY Targeted Therapies for patients with cancer", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:55.433+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "45450f7f-3658-4564-9850-13268b591e2f", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Venn diagram", "slug": "venn-diagram", "status": "active", "bestFor": null, "canonId": "019de52d-1f53-7290-96c8-79388c95fc17", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "d0b5c8ee-2541-4993-8b7c-4817b07c0702", "evidence": "diagram/venn: Venn diagram showing the intersection of Kinase Resistance and Kinase Selectivity", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:31:09.08409+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "d8c55ff4-f93f-4877-bd46-c69d1cf53245", "evidence": "Visual intersection of two concepts", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:33:55.433+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "frameworkName": "venn" } ], "arcBeats": [ { "to": 6, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 6, "name": "Solution", "beatId": "af08a215-8bda-49a9-b4de-9eba972cf7ae", "matchId": "94029b68-a5c1-4a28-8d68-beb9720b9a6d", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "The solution of precisely targeted therapies is introduced.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 9, "from": 6, "loop": { "name": "53_jobs_to_be_done", "slug": "53-jobs-to-be-done", "status": "active", "bestFor": "Product innovation, market entry, competitive positioning", "canonId": "019dd956-7b6c-7594-b5b3-eecbe0ab48e8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying", "familyLabel": null }, "matchId": "7d073297-3453-4a5f-a314-d600119c06ad", "evidence": "The need for precisely targeted therapies is discussed.", "position": 2, "objective": "What are the unmet needs in cancer treatment?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:37:21.835621+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 7, "type": "tension", "title": "Uses a visual process flow to contrast existing therapy failure with Nuvalent's solution.", "function": "frame_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "frame_problem", "functionCanon": { "name": "Frame problem", "slug": "frame_problem", "status": "active", "canonId": "019de52d-13db-753e-ad70-e9b2d0dab398", "version": 1, "description": null }, "density": "balanced", "densityScore": 30, "componentCount": 4, "textChars": 243, "nDataPoints": 0, "notes": "Uses a visual process flow to contrast existing therapy failure with Nuvalent's solution.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:33:56.169+00", "seconds": 2.877, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/7", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-7", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.65, "x": 0.3, "y": 0.15 }, "kind": "diagram", "text": "Original tumor evolving into drug-resistant tumor via mutation", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:56.169+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d4b061ac-77bb-4e10-9a8f-4474dc15607d", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.65, "x": 0.3, "y": 0.5 }, "kind": "image", "text": "Comparison of existing vs Nuvalent therapy in normal and mutated kinase scenarios", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:56.169+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fcb07e83-79f0-415d-99ab-22eebd6f2cd9", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.2, "x": 0.07, "y": 0.52 }, "kind": "paragraph", "text": "Structural innovations designed to overcome drug-resistance due to kinase mutations", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:56.169+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1b333182-745d-475f-afe1-0974b45d3bba", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.2, "x": 0.07, "y": 0.42 }, "kind": "title", "text": "Kinase Resistance", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:56.169+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c3cd9b76-c252-47b5-b86a-ad90547cc15c", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Problem Statement Canvas", "slug": "problem-statement-canvas", "status": "active", "bestFor": null, "canonId": "019dd956-839d-744b-ad11-9bf3e3642a18", "version": 1, "bodyDocId": null, "description": "Structured definition of the problem: What? Who? Where? When? Scale?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "8860dd90-b7f8-45a3-ad71-6efd107a127b", "evidence": "Structural innovations designed to overcome drug-resistance due to kinase mutations", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:31:02.951991+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "ad7de20c-240b-47ba-8f3b-dfc1a523ee71", "evidence": "Contrasts the state of existing therapy failure with the solution provided by Nuvalent.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:33:56.169+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "frameworkName": "before-after-bridge" } ], "arcBeats": [ { "to": 7, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 7, "name": "Problem", "beatId": "b7fbf414-8df7-4ba0-a8a4-eda6bab91c20", "matchId": "94029b68-a5c1-4a28-8d68-beb9720b9a6d", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "The problem of kinase resistance is clearly stated.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 12, "from": 7, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "781a9db6-60df-4e5f-9ef7-9eb3f3b812ae", "evidence": "The limitations of current treatments are discussed.", "position": 0, "objective": "What are the consequences of not addressing kinase resistance?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:37:21.755678+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 9, "from": 6, "loop": { "name": "53_jobs_to_be_done", "slug": "53-jobs-to-be-done", "status": "active", "bestFor": "Product innovation, market entry, competitive positioning", "canonId": "019dd956-7b6c-7594-b5b3-eecbe0ab48e8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying", "familyLabel": null }, "matchId": "7d073297-3453-4a5f-a314-d600119c06ad", "evidence": "The need for precisely targeted therapies is discussed.", "position": 2, "objective": "What are the unmet needs in cancer treatment?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:37:21.835621+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 8, "type": "resolution", "title": "Uses a visual comparison framework to illustrate the mechanism of action and clinical benefit of selectivity.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 44, "componentCount": 5, "textChars": 348, "nDataPoints": 0, "notes": "Uses a visual comparison framework to illustrate the mechanism of action and clinical benefit of selectivity.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:33:56.714+00", "seconds": 2.694, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/8", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-8", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.8, "w": 0.6, "x": 0.35, "y": 0.1 }, "kind": "diagram", "text": "Comparison of non-selective vs selective therapy pathways", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Value chain", "slug": "value-chain", "status": "active", "canonId": "019de52d-048a-769c-aad6-4abdde7ef317", "version": 1, "description": null }, "framework": null }, "subkind": "value-chain", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:56.714+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e75ec286-2752-4c67-b6db-87cf6e6ea53b", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.15, "x": 0.81, "y": 0.28 }, "kind": "legend", "text": "Selective inhibition potentially minimizes toxicities", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:56.714+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1d0926f4-681c-4ae7-be47-49754fed5f6d", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.15, "x": 0.52, "y": 0.8 }, "kind": "legend", "text": "Adverse events due to off-target inhibition", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:56.714+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ab3a8ea4-5a73-4255-a8be-27a535be48c7", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.25, "x": 0.07, "y": 0.56 }, "kind": "paragraph", "text": "Structural innovations designed to increase selectivity to potentially minimize therapy-limiting adverse events related to off-target inhibition AND drive more durable responses", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:56.714+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c9d0a36f-4833-4a93-b4c4-5d4d5ef14429", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.2, "x": 0.07, "y": 0.42 }, "kind": "title", "text": "Kinase Selectivity", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:56.714+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "220b272f-883d-4d97-b866-6e6c066cdffa", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "9c4594c3-3e95-4b02-a927-ec2546eb8c71", "evidence": "Side-by-side visual comparison of non-selective vs selective therapy", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:33:56.714+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "frameworkName": "comparison-frame" } ], "arcBeats": [], "loops": [ { "to": 12, "from": 7, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "781a9db6-60df-4e5f-9ef7-9eb3f3b812ae", "evidence": "The limitations of current treatments are discussed.", "position": 0, "objective": "What are the consequences of not addressing kinase resistance?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:37:21.755678+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 9, "from": 6, "loop": { "name": "53_jobs_to_be_done", "slug": "53-jobs-to-be-done", "status": "active", "bestFor": "Product innovation, market entry, competitive positioning", "canonId": "019dd956-7b6c-7594-b5b3-eecbe0ab48e8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying", "familyLabel": null }, "matchId": "7d073297-3453-4a5f-a314-d600119c06ad", "evidence": "The need for precisely targeted therapies is discussed.", "position": 2, "objective": "What are the unmet needs in cancer treatment?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:37:21.835621+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 9, "type": "resolution", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 54, "componentCount": 7, "textChars": 273, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:33:56.739+00", "seconds": 2.714, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/9", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-9", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.5, "w": 0.06, "x": 0.51, "y": 0.26 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Icon grid", "slug": "icon-grid", "status": "active", "canonId": "019de52c-fdfe-749d-9990-1db465a3eed4", "version": 1, "description": null }, "framework": null }, "subkind": "icon-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:56.739+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e19efd94-0b3b-4632-9253-07f1584ec60c", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.3, "x": 0.585, "y": 0.715 }, "kind": "list", "text": "TRK sparing to minimize CNS adverse events", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:56.739+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "31005b28-e30d-47c1-920b-1cb91b6bddf2", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.35, "x": 0.585, "y": 0.405 }, "kind": "list", "text": "Active against treatment-emergent ROS1 resistance mutations: G2032R, D2033N, L2026M, S1986Y/F", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:56.739+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5981f830-443f-4489-b37d-34cb58ed39c1", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.15, "x": 0.585, "y": 0.59 }, "kind": "list", "text": "Brain penetrant", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:56.739+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b6b4f0b5-5f40-4e08-bb97-d4422817316e", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.3, "x": 0.585, "y": 0.29 }, "kind": "list", "text": "Active against wild-type ROS1 fusions", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:56.739+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c321bedd-c9f9-4c03-b662-0a7ab771f803", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.25, "x": 0.512, "y": 0.188 }, "kind": "title", "text": "TARGET PRODUCT PROFILE:", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:56.739+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4e25b7d1-2489-480b-9426-eb5e2df1ea74", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.33, "x": 0.105, "y": 0.315 }, "kind": "title", "text": "NVL-520 for ROS1-Positive Advanced NSCLC and other Solid Tumors", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:56.739+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bda2a4dd-21e8-4cc2-8127-bd76b7d3b27e", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "8572f4a5-321f-41cd-9e56-4dedeec4905c", "evidence": "Active against treatment-emergent ROS1 resistance mutations: G2032R, D2033N, L2026M, S1986Y/F", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:31:03.074016+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [ { "to": 12, "from": 7, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "781a9db6-60df-4e5f-9ef7-9eb3f3b812ae", "evidence": "The limitations of current treatments are discussed.", "position": 0, "objective": "What are the consequences of not addressing kinase resistance?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:37:21.755678+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 9, "from": 6, "loop": { "name": "53_jobs_to_be_done", "slug": "53-jobs-to-be-done", "status": "active", "bestFor": "Product innovation, market entry, competitive positioning", "canonId": "019dd956-7b6c-7594-b5b3-eecbe0ab48e8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit", "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying", "familyLabel": null }, "matchId": "7d073297-3453-4a5f-a314-d600119c06ad", "evidence": "The need for precisely targeted therapies is discussed.", "position": 2, "objective": "What are the unmet needs in cancer treatment?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:37:21.835621+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 10, "type": "resolution", "title": "The slide highlights the clinical need for new therapies due to resistance mutations (G2032R) and CNS involvement.", "function": "size_opportunity", "rawType": "market_sizing", "block": null, "metadata": { "slideType": "market_sizing", "slideTypeCanon": { "name": "Market sizing", "slug": "market_sizing", "status": "active", "canonId": "019de52d-08c8-756c-8664-733b73a7ee7b", "version": 1, "description": null }, "function": "size_opportunity", "functionCanon": { "name": "Size opportunity", "slug": "size_opportunity", "status": "active", "canonId": "019de52d-147b-7568-8828-a74a27697618", "version": 1, "description": null }, "density": "balanced", "densityScore": 44, "componentCount": 4, "textChars": 348, "nDataPoints": 6, "notes": "The slide highlights the clinical need for new therapies due to resistance mutations (G2032R) and CNS involvement.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:34:00.302+00", "seconds": 6.236, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/10", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-10", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.02, "w": 0.51, "x": 0.076, "y": 0.895 }, "kind": "source-note", "text": "Sources: Lin et al., J Thorac Oncol 2017; Gainor et al, JCO Precision Oncol 2017; Ou and Zhu Lung Cancer 2019; Patil et al, JTO 2018", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.302+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6be118ce-03b7-4608-9fb3-b0feff8d27f6", "parentComponentId": null }, { "bbox": { "h": 0.495, "w": 0.864, "x": 0.068, "y": 0.305 }, "kind": "table", "text": "Line of Therapy, Sub-population, Incidence (US), CNS Disease, Standard of Care (2022)", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.302+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "50019560-79b6-4e32-9a51-fdd8593612f0", "parentComponentId": null }, { "bbox": { "h": 0.025, "w": 0.685, "x": 0.076, "y": 0.185 }, "kind": "title", "text": "Emerging resistance mutations and increasing CNS involvement limit utility of approved therapies", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.302+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d8058882-dd0e-4513-b648-85decc413fe5", "parentComponentId": null }, { "bbox": { "h": 0.045, "w": 0.415, "x": 0.076, "y": 0.115 }, "kind": "title", "text": "ROS1-positive NSCLC Market Overview", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.302+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "74de6568-ec9e-4f67-82e6-12bb1dea4deb", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Market Segmentation Pyramid", "slug": "market-segmentation-pyramid", "status": "active", "bestFor": null, "canonId": "1c9f3543-c96f-4a5b-b4a4-9b2a412c0aaf", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "c2e9a912-1259-437b-9377-64b47b091262", "evidence": "ROS1-positive NSCLC Market Overview", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:31:03.155994+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "4b69bf1d-4070-4662-b161-e96c9c0e96e7", "evidence": "Line of Therapy, Sub-population, Incidence (US), CNS Disease, Standard of Care (2022)", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:31:03.196994+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "74e5d306-f6f2-40eb-8437-b8542677fbbe", "evidence": "Segments market by line of therapy and mutation status", "framework": null, "confidence": 0.7, "extraction": { "at": "2026-05-02 11:34:00.302+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "frameworkName": "market-segmentation-pyramid" } ], "arcBeats": [ { "to": 10, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 10, "name": "Market Sizing", "beatId": "4cedff80-36c0-4bbc-a462-ced06248d8ee", "matchId": "94029b68-a5c1-4a28-8d68-beb9720b9a6d", "beatType": null, "evidence": "The market for ROS1-positive NSCLC is sized.", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 12, "from": 7, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "781a9db6-60df-4e5f-9ef7-9eb3f3b812ae", "evidence": "The limitations of current treatments are discussed.", "position": 0, "objective": "What are the consequences of not addressing kinase resistance?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:37:21.755678+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 11, "type": "setup", "title": "The table uses a green background to indicate positive results ('Yes') and white for negative results ('No').", "function": "compare_peers", "rawType": "competitive_analysis", "block": null, "metadata": { "slideType": "competitive_analysis", "slideTypeCanon": { "name": "Competitive analysis", "slug": "competitive_analysis", "status": "active", "canonId": "019de52d-093e-776b-94c6-c1573f5f1a31", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "balanced", "densityScore": 46, "componentCount": 4, "textChars": 354, "nDataPoints": 20, "notes": "The table uses a green background to indicate positive results ('Yes') and white for negative results ('No').", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:33:58.509+00", "seconds": 4.384, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/11", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-11", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.06, "w": 0.85, "x": 0.076, "y": 0.865 }, "kind": "disclaimer", "text": "No head-to-head clinical studies have been conducted for currently approved or investigational therapies versus NVL-520. Clinical investigation of NVL-520 is ongoing.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:58.509+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2e3b6b4e-2119-404b-8e1a-ff860ea7ccdf", "parentComponentId": null }, { "bbox": { "h": 0.58, "w": 0.86, "x": 0.069, "y": 0.25 }, "kind": "table", "text": "Comparison matrix of NVL-520 vs Crizotinib, Entrectinib, Lorlatinib, and Repotrectinib across 4 activity categories.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:58.509+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a74998d0-5f9f-4543-a90b-92c88e23ffcd", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.51, "x": 0.076, "y": 0.188 }, "kind": "title", "text": "Differentiated Product Candidate for ROS1-positive NSCLC Patients", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:58.509+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6be6f6d2-42cb-4750-b65f-dee8d8f05a2a", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.19, "x": 0.076, "y": 0.115 }, "kind": "title", "text": "NVL-520", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:58.509+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d09092f8-3078-41c3-bd5a-500bcc1bce25", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "2x2 matrix", "slug": "matrix-2x2", "status": "active", "bestFor": null, "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8", "version": 1, "bodyDocId": null, "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "2303063c-957d-43f3-80e4-064143ab5743", "evidence": "Comparison matrix of NVL-520 vs Crizotinib, Entrectinib, Lorlatinib, and Repotrectinib across 4 activity categories.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:31:03.279032+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 11, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "aa70cc1c-3596-4f37-a670-77408dd3edf3", "evidence": "Table comparing product features against competitors", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:33:58.509+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 11, "frameworkName": "comparison_frame" } ], "arcBeats": [ { "to": 11, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 11, "name": "Competitive Analysis", "beatId": "7a498776-5a16-472f-bc57-dc9a095453a4", "matchId": "94029b68-a5c1-4a28-8d68-beb9720b9a6d", "beatType": { "name": "Competition", "slug": "sequoia-pitch-competition", "status": "active", "canonId": "019dd9b8-21bd-7407-8707-bdf217ed9c76", "version": 1, "description": null }, "evidence": "NVL-520 is compared to existing treatments.", "position": 4, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 12, "from": 7, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "781a9db6-60df-4e5f-9ef7-9eb3f3b812ae", "evidence": "The limitations of current treatments are discussed.", "position": 0, "objective": "What are the consequences of not addressing kinase resistance?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:37:21.755678+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 12, "type": "tension", "title": "The slide uses a human anatomy diagram to map specific TRK receptor inhibition side effects to body regions.", "function": "frame_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "frame_problem", "functionCanon": { "name": "Frame problem", "slug": "frame_problem", "status": "active", "canonId": "019de52d-13db-753e-ad70-e9b2d0dab398", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 76, "componentCount": 8, "textChars": 724, "nDataPoints": 0, "notes": "The slide uses a human anatomy diagram to map specific TRK receptor inhibition side effects to body regions.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:33:57.682+00", "seconds": 3.398, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/12", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-12", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.04, "w": 0.35, "x": 0.43, "y": 0.17 }, "kind": "callout", "text": "TRK INHIBITION SAFETY IMPLICATIONS", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:57.682+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cc695d42-81a9-437b-9800-dbdc539685ee", "parentComponentId": null }, { "bbox": { "h": 0.85, "w": 0.22, "x": 0.75, "y": 0.08 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:57.682+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "930e9daa-764e-4219-8112-e0daf5049371", "parentComponentId": null }, { "bbox": { "h": 0.18, "w": 0.35, "x": 0.43, "y": 0.45 }, "kind": "list", "text": "TRKC: Impairment of motor neuron afferents and loss of dorsal root ganglia neurons; Defect in proprioception", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:57.682+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1ab76755-4c35-4ae6-aec0-8c4b3d9061b6", "parentComponentId": null }, { "bbox": { "h": 0.18, "w": 0.35, "x": 0.43, "y": 0.22 }, "kind": "list", "text": "TRKB: Impairments in memory, learning and nociception; Development of obesity caused by hyperphagia and hyperdipsia", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:57.682+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ce8a0d0e-e78b-4b01-8744-dd7e9f65a667", "parentComponentId": null }, { "bbox": { "h": 0.18, "w": 0.35, "x": 0.43, "y": 0.68 }, "kind": "list", "text": "TRKA: Congenital insensitivity to pain with anhidrosis (CIPA); Severe sensory and sympathetic neuropathies", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:57.682+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e6dab9da-6ce9-4570-a79e-d4e3bb61b7ed", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.32, "x": 0.07, "y": 0.36 }, "kind": "paragraph", "text": "ROS1 and ALK both share strong structural similarities to TRK. Brain penetration is needed to address associated CNS disease in ROS1 and ALK driven cancers. Inhibitors must be highly selective to avoid CNS toxicities from off-target inhibition of TRK", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:57.682+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "88fa5fc5-adf3-4eee-93bf-f5e6b7d9886e", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.3, "x": 0.07, "y": 0.89 }, "kind": "source-note", "text": "Sources: Adapted from Cocco, Scaltriti and Drilon Nat Rev Clin Oncol 2018", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:57.682+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b1cc8293-0b1d-49aa-9d88-7202368fb930", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.35, "x": 0.07, "y": 0.21 }, "kind": "title", "text": "Overcoming Kinase Selectivity in NSCLC", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:57.682+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "30805082-5e9c-4d6e-9bfd-adee9b79f541", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Problem-Agitate-Solve (PAS)", "slug": "problem-agitate-solve-pas", "status": "active", "bestFor": null, "canonId": "019dd956-869f-7564-8d42-de54ed29ab90", "version": 1, "bodyDocId": null, "description": "Identify problem, agitate the pain, present the solution", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "50a1cd82-c556-4b6d-8774-4fc350cdbd2e", "evidence": "ROS1 and ALK both share strong structural similarities to TRK.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.6, "extraction": { "at": "2026-07-17 00:31:03.362606+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [ { "to": 12, "from": 7, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "781a9db6-60df-4e5f-9ef7-9eb3f3b812ae", "evidence": "The limitations of current treatments are discussed.", "position": 0, "objective": "What are the consequences of not addressing kinase resistance?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:37:21.755678+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 13, "type": "resolution", "title": "The slide uses dot plots for IC50 data and a bar chart for tumor regression efficacy.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 61, "componentCount": 5, "textChars": 488, "nDataPoints": 40, "notes": "The slide uses dot plots for IC50 data and a bar chart for tumor regression efficacy.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:33:57.494+00", "seconds": 2.976, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/13", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-13", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.35, "w": 0.28, "x": 0.67, "y": 0.35 }, "kind": "chart", "text": "In vivo efficacy tumor regression bar chart", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:57.494+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "73605028-cbd8-41f1-a1f8-32958dd16bc7", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.28, "x": 0.08, "y": 0.35 }, "kind": "chart", "text": "Fusion Partners IC50 dot plot", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Dot plot", "slug": "dot", "status": "active", "canonId": "019de52d-0235-738b-bd2b-78f8e24d7cb0", "version": 1, "description": null }, "framework": null }, "subkind": "dot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:57.494+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "40b72699-c685-4250-9d56-d8a369b493ed", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.28, "x": 0.37, "y": 0.35 }, "kind": "chart", "text": "Resistance Mutations IC50 dot plot", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Dot plot", "slug": "dot", "status": "active", "canonId": "019de52d-0235-738b-bd2b-78f8e24d7cb0", "version": 1, "description": null }, "framework": null }, "subkind": "dot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:57.494+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "824edbd9-3615-4611-b276-1df04975a482", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.75, "x": 0.07, "y": 0.9 }, "kind": "source-note", "text": "BID, twice daily; IC50, half-maximal inhibitory concentration; PDC, patient-derived cell line. Sources: Drilon A. et al., Cancer Discov (2023) 13 (3): 598–615.; Tangpeerachaikul, A. et al., AACR 2022; Deshpande, A. et al., EORTC-NCI-AACR 2021; Pelish, H.E. et al., AACR 2021.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:57.494+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6f8f63d1-d441-4f02-a7f6-f59b5995d694", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.85, "x": 0.07, "y": 0.06 }, "kind": "title", "text": "Preclinical | NVL-520 Exhibits Potent Activity Across Diverse ROS1 Fusion Partners and Resistance Mutations", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:57.494+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e268a0f0-fa06-4262-8729-b7064742d914", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "b2423d13-7dd4-4e25-b72f-e773be805b3a", "evidence": "In vivo efficacy tumor regression bar chart", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.6, "extraction": { "at": "2026-07-17 00:31:03.446295+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 14, "type": "resolution", "title": "The slide uses a bar chart to compare brain penetrance and a grouped bar chart to show selectivity indices across multiple drugs.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 56, "componentCount": 4, "textChars": 641, "nDataPoints": 10, "notes": "The slide uses a bar chart to compare brain penetrance and a grouped bar chart to show selectivity indices across multiple drugs.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:33:57.854+00", "seconds": 3.3, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/14", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-14", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.5, "w": 0.48, "x": 0.42, "y": 0.35 }, "kind": "chart", "text": "Selectivity Index for NVL-520, Crizotinib, Entrectinib, Repotrectinib", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Grouped bar chart", "slug": "bar-grouped", "status": "active", "canonId": "019de52c-ff3b-751e-a8ff-f21ff11097b1", "version": 1, "description": null }, "framework": null }, "subkind": "bar-grouped", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:57.854+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "223a8b6a-64a4-465a-9b4f-6c6a4bf5e924", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.25, "x": 0.08, "y": 0.42 }, "kind": "chart", "text": "Unbound brain:plasma ratio for NVL-520 vs Lorlatinib", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:57.854+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c22eeacd-6f45-4426-a0c2-a4f42e926e04", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.7, "x": 0.07, "y": 0.88 }, "kind": "source-note", "text": "IC50, half-maximal inhibitory concentration; PO, orally; pTRK, BDNF-stimulated TRKB phosphorylation. Head-to-head clinical studies comparing NVL-520 with currently approved or investigational therapies have not been conducted. Above data from preclinical studies. Sources: Drilon A. et al., Cancer Discov (2023) 13 (3): 598–615.; Tangpeerachaikul, A. et al., EORTC-NCI-AACR 2021; Data on file.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:57.854+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0eb9e378-72e0-4e94-9ce3-0efdfac060c3", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.85, "x": 0.07, "y": 0.06 }, "kind": "title", "text": "Preclinical | NVL-520 is a Brain Penetrant, ROS1-Selective Inhibitor with the Potential to Avoid TRK-Related CNS Adverse Events", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:57.854+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "297c366d-410e-4067-8d6f-11e5e9f7bf06", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 15, "type": "setup", "title": "Includes a detailed table of Phase 2 cohorts and a list of study objectives.", "function": "present_framework", "rawType": "appendix_methodology", "block": null, "metadata": { "slideType": "appendix_methodology", "slideTypeCanon": { "name": "Appendix methodology", "slug": "appendix_methodology", "status": "active", "canonId": "019de52d-07d9-726c-8599-167f2d2ffaa7", "version": 1, "description": null }, "function": "present_framework", "functionCanon": { "name": "Present framework", "slug": "present_framework", "status": "active", "canonId": "019de52d-1403-7667-9100-d2ac6709f750", "version": 1, "description": null }, "density": "dense", "densityScore": 61, "componentCount": 5, "textChars": 1027, "nDataPoints": 0, "notes": "Includes a detailed table of Phase 2 cohorts and a list of study objectives.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:33:58.129+00", "seconds": 3.573, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/15", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-15", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.55, "w": 0.42, "x": 0.07, "y": 0.25 }, "kind": "list", "text": "Phase 1 Dose-Escalation: Patient Population and Objectives", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:58.129+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dba654ba-bf88-48b7-85fc-b19aa5772216", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.44, "x": 0.49, "y": 0.62 }, "kind": "paragraph", "text": "Objectives for Phase 2 cohorts and design intent for registration.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:58.129+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ebffd211-2a42-419c-8349-e831bb8b45be", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.86, "x": 0.07, "y": 0.85 }, "kind": "source-note", "text": "CBR, clinical benefit rate; Chemo/I-O, platinum-based chemotherapy ± immunotherapy; DOR, duration of response; MTD, maximum tolerated dose; NSCLC, non-small cell lung cancer; ORR, overall response rate (RECIST 1.1); OS, overall survival; PFS, progression-free survival; PK, pharmacokinetics; RP2D, recommended phase 2 dose; ROS1+, ROS1-positive; TKI, tyrosine kinase inhibitor; TTR, time to response. a Patients with baseline concurrent oncogenic drivers identified on subsequent testing and patients without measurable disease are excluded from efficacy evaluation per prespecified protocol analysis plan. Source: Drilon A. et al., EORTC-NCI-AACR 2022.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:58.129+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "99869a75-e40b-4943-9586-6368793e2dee", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.44, "x": 0.49, "y": 0.25 }, "kind": "table", "text": "Open-Label Phase 2 Cohorts (Planned) table with columns: Cohort, Tumor Type, Prior ROS1 TKI, Prior Chemo/I-O", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:58.129+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c01ba39f-341a-4430-9dc8-4075468f1386", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.85, "x": 0.07, "y": 0.06 }, "kind": "title", "text": "Study Design | ARROS-1: A Global Phase 1/2 Study of NVL-520 in Patients with Advanced ROS1-Positive NSCLC and Other Solid Tumors (NCT05118789)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:58.129+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "04c343ce-8263-462c-b133-e676c5dcb82a", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 16, "type": "analysis", "title": "The slide details the transition from the All-Treated Population (N=35) to the NSCLC Response-Evaluable Population (N=21) through back-fill expansion.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "balanced", "densityScore": 46, "componentCount": 4, "textChars": 356, "nDataPoints": 20, "notes": "The slide details the transition from the All-Treated Population (N=35) to the NSCLC Response-Evaluable Population (N=21) through back-fill expansion.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:33:57.715+00", "seconds": 3.15, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/16", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-16", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.45, "w": 0.84, "x": 0.08, "y": 0.36 }, "kind": "diagram", "text": "Flow diagram showing dose levels, back-fill additions, and response-evaluable population counts.", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:57.715+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c5e5db49-949f-48f1-a01b-64fed4637777", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.3, "x": 0.08, "y": 0.21 }, "kind": "paragraph", "text": "All-Treated Population (N = 35)", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:57.715+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "af450a74-0925-485d-8a3b-473a7e2a399e", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.84, "x": 0.08, "y": 0.86 }, "kind": "source-note", "text": "Data as of 13 Sep 22, for patients treated by 01 Sep 2022. mg, milligram; NSCLC, non-small cell lung cancer; QD, once daily. a First response evaluation is pending for 6 patients...", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:57.715+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "94d00388-d68a-452b-8f23-a98fa0a76811", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.07, "y": 0.08 }, "kind": "title", "text": "Cohort Accrual | ARROS-1 Phase 1 Dose-Escalation", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:57.715+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "61bc4de3-a328-45f2-913a-b1a69f05666c", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 17, "type": "analysis", "title": "Clinical trial baseline characteristics table.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "balanced", "densityScore": 48, "componentCount": 3, "textChars": 594, "nDataPoints": 30, "notes": "Clinical trial baseline characteristics table.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:33:57.558+00", "seconds": 2.926, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/17", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-17", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.12, "w": 0.45, "x": 0.07, "y": 0.78 }, "kind": "source-note", "text": "Data as of 13 Sep 22, for patients treated by 01 Sep 2022. All data shown as n (%) unless otherwise specified. CNS, central nervous system; ECOG PS, Eastern Cooperative Oncology Group performance status; NSCLC, non-small cell lung cancer; RECIST 1.1, Response Evaluation Criteria in Solid Tumours version 1.1; TKI, tyrosine kinase inhibitor. a Includes patients with untreated CNS lesions. b Categories are not mutually exclusive. Source: Drilon A. et al., EORTC-NCI-AACR 2022.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:57.558+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a1fadc13-29db-4fc0-b7ba-10385849615f", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.86, "x": 0.07, "y": 0.2 }, "kind": "table", "text": "Patient characteristics and treatment history table", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:57.558+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2e39a130-d14c-4073-a754-c1ba474257da", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.07, "y": 0.08 }, "kind": "title", "text": "ARROS-1 Phase 1 Population | Heavily Pretreated ROS1+ Solid Tumors", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:57.558+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c1d3de59-4643-46f7-92e3-4151567b9b84", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "2a5c414b-b7ff-46ef-a111-72d2f3040a0f", "evidence": "Patient characteristics and treatment history table", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:31:03.654721+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 17, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 18, "type": "analysis", "title": "Data as of 13 Sep 22. Table lists specific adverse events by grade.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 56, "componentCount": 4, "textChars": 602, "nDataPoints": 24, "notes": "Data as of 13 Sep 22. Table lists specific adverse events by grade.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:33:57.814+00", "seconds": 3.106, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/18", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-18", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.3, "w": 0.3, "x": 0.07, "y": 0.325 }, "kind": "list", "text": "No DLTs\nNo treatment-related SAEs\nNo AEs leading to dose reduction or discontinuation\nNo treatment-related dizziness", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:57.814+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "03b7e4d1-2c47-4a21-a861-6672a24ab168", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.8, "x": 0.07, "y": 0.85 }, "kind": "source-note", "text": "Data as of 13 Sep 22, for patients treated by 01 Sep 2022. AE, adverse event; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; DLT, dose-limiting toxicity; SAE, serious adverse event. a Including oedema and oedema peripheral. Source: Drilon A. et al., EORTC-NCI-AACR 2022.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:57.814+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c6143ebf-3a05-4629-a68e-4e526adf427b", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.52, "x": 0.396, "y": 0.258 }, "kind": "table", "text": "Treatment-Related Adverse Events (TRAEs) in >1 Patient All Treated Patients (N = 35)", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:57.814+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a4a14e39-fd89-413b-b574-171ff016cc6f", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.85, "x": 0.07, "y": 0.06 }, "kind": "title", "text": "Preliminary Safety Profile | Favorable and Consistent with the Highly ROS1-Selective, TRK-Sparing Design of NVL-520", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:57.814+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "168eb744-621a-486f-bc69-32151d9ac5ef", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 19, "type": "evidence", "title": "The chart displays dose-dependent exposure levels exceeding multiple efficacy targets (ROS1 G2032R and Wild Type in CNS and periphery).", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 53, "componentCount": 4, "textChars": 607, "nDataPoints": 4, "notes": "The chart displays dose-dependent exposure levels exceeding multiple efficacy targets (ROS1 G2032R and Wild Type in CNS and periphery).", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:33:57.995+00", "seconds": 2.973, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/19", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-19", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.615, "w": 0.435, "x": 0.095, "y": 0.275 }, "kind": "chart", "text": "Pharmacokinetic concentration over time chart", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:57.995+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5aa1814e-66c5-4cd2-add3-880e49defdfd", "parentComponentId": null }, { "bbox": { "h": 0.095, "w": 0.835, "x": 0.082, "y": 0.835 }, "kind": "disclaimer", "text": "Data as of 13 Sep 22, for patients treated by 01 Sep 2022. Pharmacokinetic data for 125 mg QD cohort are not shown due to immaturity. CNS, central nervous system; h, hours; PK, pharmacokinetics; QD, once daily; SD, standard deviation.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:57.995+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cfe16823-a4e8-47d5-b026-fca368e61ad6", "parentComponentId": null }, { "bbox": { "h": 0.32, "w": 0.33, "x": 0.585, "y": 0.285 }, "kind": "list", "text": "NVL-520 exposure exceeded target levels that provide regression in preclinical models. Favorable pharmacokinetics: Low intra-cohort patient PK variability, Exposure increasing with increasing dose level, Half-life of approximately 20h supports QD dosing.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:57.995+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d714d3aa-b7a1-40a9-b5be-3b4aab60b467", "parentComponentId": null }, { "bbox": { "h": 0.115, "w": 0.845, "x": 0.077, "y": 0.065 }, "kind": "title", "text": "Pharmacokinetics | NVL-520 Exposure Exceeded Predicted Efficacy Thresholds", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:57.995+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "909fbd42-9172-4253-b5ed-a4ce944985d0", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "5c15b005-3fc5-48e0-8459-3f1f03d48bd6", "evidence": "chart/line: Pharmacokinetic concentration over time chart", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:31:02.624807+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 19, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 24, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 19, "name": "Traction", "beatId": "fe8c99d1-59ae-4350-9a12-ffd07cd22e0a", "matchId": "94029b68-a5c1-4a28-8d68-beb9720b9a6d", "beatType": null, "evidence": "Preliminary efficacy and safety data are presented.", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 24, "from": 19, "loop": { "name": "14_day_in_life", "slug": "14-day-in-life", "status": "active", "bestFor": "Product demos, UX reviews, investor pitches focusing on pain points", "canonId": "019dd956-6b65-707f-9b14-89beaaab81fa", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The User's Struggle -> The Intervention (Your Solution) -> The Resolved State", "description": "Humanize abstract data by walking through a single user's struggle and resolution", "familyLabel": null }, "matchId": "a5849bfd-1f57-46db-8128-2b35af72eb66", "evidence": "Preliminary efficacy data are presented.", "position": 1, "objective": "How do patients benefit from Nuvalent's therapies?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:37:21.795555+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 20, "type": "evidence", "title": "Clinical trial data presentation for NVL-520.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "balanced", "densityScore": 33, "componentCount": 3, "textChars": 267, "nDataPoints": 35, "notes": "Clinical trial data presentation for NVL-520.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:33:59.784+00", "seconds": 4.718, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/20", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-20", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.85, "x": 0.07, "y": 0.82 }, "kind": "disclaimer", "text": "Data as of 13 Sep 22... Source: Drilon A. et al., EORTC-NCI-AACR 2022.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:59.784+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "39f1128a-7048-4504-8879-f3a280c4dd7d", "parentComponentId": null }, { "bbox": { "h": 0.58, "w": 0.85, "x": 0.07, "y": 0.24 }, "kind": "table", "text": "Table showing patient counts and response rates (ORR, PR, SD, PD, NE) across five patient cohorts.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:59.784+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "52fe99f2-871f-4b84-a35c-1ae6ddfb09ba", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.85, "x": 0.07, "y": 0.06 }, "kind": "title", "text": "Preliminary Efficacy | NVL-520 Induced Tumor Response Across Heavily Pretreated Patient Populations", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:59.784+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "838c9d1b-ab8a-4d62-b51b-db6b4f6ad5d3", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 24, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 19, "name": "Traction", "beatId": "fe8c99d1-59ae-4350-9a12-ffd07cd22e0a", "matchId": "94029b68-a5c1-4a28-8d68-beb9720b9a6d", "beatType": null, "evidence": "Preliminary efficacy and safety data are presented.", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 24, "from": 19, "loop": { "name": "14_day_in_life", "slug": "14-day-in-life", "status": "active", "bestFor": "Product demos, UX reviews, investor pitches focusing on pain points", "canonId": "019dd956-6b65-707f-9b14-89beaaab81fa", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The User's Struggle -> The Intervention (Your Solution) -> The Resolved State", "description": "Humanize abstract data by walking through a single user's struggle and resolution", "familyLabel": null }, "matchId": "a5849bfd-1f57-46db-8128-2b35af72eb66", "evidence": "Preliminary efficacy data are presented.", "position": 1, "objective": "How do patients benefit from Nuvalent's therapies?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:37:21.795555+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 21, "type": "evidence", "title": "The chart uses a waterfall plot to visualize clinical efficacy, a standard in oncology drug development.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 54, "componentCount": 5, "textChars": 347, "nDataPoints": 17, "notes": "The chart uses a waterfall plot to visualize clinical efficacy, a standard in oncology drug development.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:33:58.073+00", "seconds": 2.916, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/21", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-21", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.55, "w": 0.75, "x": 0.17, "y": 0.18 }, "kind": "chart", "text": "Waterfall plot of best percentage change in target lesions", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Waterfall chart", "slug": "waterfall", "status": "active", "canonId": "019de52d-002e-733e-b5cf-dd3beb6692cc", "version": 1, "description": null }, "framework": null }, "subkind": "waterfall", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:58.073+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ef956268-143b-4324-a3df-6988dfe7b4ea", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.85, "x": 0.07, "y": 0.85 }, "kind": "disclaimer", "text": "Data as of 13 Sep 22, for response-evaluable patients with NSCLC treated by 01 Sep 2022. Source: Drilon A. et al., EORTC-NCI-AACR 2022.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:58.073+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "20c84026-b26c-428e-8290-514f60c4677b", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.08, "x": 0.07, "y": 0.25 }, "kind": "legend", "text": "Dose level color key", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:58.073+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "61f3cfa1-7607-4797-85fa-6da24b968db9", "parentComponentId": null }, { "bbox": { "h": 0.22, "w": 0.85, "x": 0.07, "y": 0.62 }, "kind": "table", "text": "Dose level and prior therapy history table", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:58.073+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "28f0f3b6-c007-4603-9b0c-7b157e03a006", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.85, "x": 0.07, "y": 0.06 }, "kind": "title", "text": "Preliminary Efficacy | Radiographic Tumor Regression Observed Across All NVL-520 Dose Levels", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:58.073+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b8358ef3-3e00-45ea-9ed1-7d54ba68d975", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "763b8443-acb9-467b-9ee8-c0d325ed661a", "evidence": "chart/waterfall: Waterfall plot of best percentage change in target lesions", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:31:02.722736+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 21, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 24, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 19, "name": "Traction", "beatId": "fe8c99d1-59ae-4350-9a12-ffd07cd22e0a", "matchId": "94029b68-a5c1-4a28-8d68-beb9720b9a6d", "beatType": null, "evidence": "Preliminary efficacy and safety data are presented.", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 24, "from": 19, "loop": { "name": "14_day_in_life", "slug": "14-day-in-life", "status": "active", "bestFor": "Product demos, UX reviews, investor pitches focusing on pain points", "canonId": "019dd956-6b65-707f-9b14-89beaaab81fa", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The User's Struggle -> The Intervention (Your Solution) -> The Resolved State", "description": "Humanize abstract data by walking through a single user's struggle and resolution", "familyLabel": null }, "matchId": "a5849bfd-1f57-46db-8128-2b35af72eb66", "evidence": "Preliminary efficacy data are presented.", "position": 1, "objective": "How do patients benefit from Nuvalent's therapies?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:37:21.795555+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 22, "type": "evidence", "title": "The chart is a swimmer plot (a common clinical trial visualization).", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 60, "componentCount": 5, "textChars": 556, "nDataPoints": 4, "notes": "The chart is a swimmer plot (a common clinical trial visualization).", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:33:58.52+00", "seconds": 3.303, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/22", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-22", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.65, "x": 0.07, "y": 0.18 }, "kind": "chart", "text": "Swimmer plot of treatment duration by patient", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:58.52+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "77bfa495-5701-4e01-ae6c-9459bab334a7", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.75, "x": 0.07, "y": 0.875 }, "kind": "disclaimer", "text": "Data as of 13 Sep 22, for response-evaluable patients with NSCLC treated by 01 Sep 2022. PD, progressive disease; PR, partial response; QD, once daily; TKI, tyrosine kinase inhibitor. Source: Drilon A. et al., EORTC-NCI-AACR 2022.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:58.52+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1e37abac-761d-4ec2-bf54-3517d036e680", "parentComponentId": null }, { "bbox": { "h": 0.21, "w": 0.22, "x": 0.715, "y": 0.36 }, "kind": "legend", "text": "Legend for treatment types, response status, and ongoing status", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:58.52+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e15e0721-2596-4656-8f59-cb7c002ac5b3", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.48, "x": 0.43, "y": 0.64 }, "kind": "list", "text": "76% (16/21) response-evaluable patients continue treatment; Median duration 3.6 months; No discontinuation due to toxicity; Median time to response 3.6 weeks", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:58.52+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c2fc4d67-c4f3-4828-aa3e-cea691945a92", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.07, "y": 0.08 }, "kind": "title", "text": "Time on Treatment | Sustained Duration with Follow-up Ongoing", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:58.52+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "22adfc62-85ea-48fd-8447-a8e1df0a2be3", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Sparklines (Chart)", "slug": "sparklines-chart", "status": "active", "bestFor": null, "canonId": "019dd956-b3db-7239-aa95-d24b7cdc29e4", "version": 1, "bodyDocId": null, "description": "Word-sized graphics embedded in text for data density", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "29000ee1-a04f-4dcc-92cf-a8121c6957e0", "evidence": "chart/bar-horizontal: Swimmer plot of treatment duration by patient", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:31:02.788974+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 22, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 24, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 19, "name": "Traction", "beatId": "fe8c99d1-59ae-4350-9a12-ffd07cd22e0a", "matchId": "94029b68-a5c1-4a28-8d68-beb9720b9a6d", "beatType": null, "evidence": "Preliminary efficacy and safety data are presented.", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 24, "from": 19, "loop": { "name": "14_day_in_life", "slug": "14-day-in-life", "status": "active", "bestFor": "Product demos, UX reviews, investor pitches focusing on pain points", "canonId": "019dd956-6b65-707f-9b14-89beaaab81fa", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The User's Struggle -> The Intervention (Your Solution) -> The Resolved State", "description": "Humanize abstract data by walking through a single user's struggle and resolution", "familyLabel": null }, "matchId": "a5849bfd-1f57-46db-8128-2b35af72eb66", "evidence": "Preliminary efficacy data are presented.", "position": 1, "objective": "How do patients benefit from Nuvalent's therapies?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:37:21.795555+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 23, "type": "evidence", "title": "Includes clinical trial data (ORR, tumor shrinkage, allele clearance) for a specific drug candidate.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 73, "componentCount": 6, "textChars": 654, "nDataPoints": 16, "notes": "Includes clinical trial data (ORR, tumor shrinkage, allele clearance) for a specific drug candidate.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:34:02.167+00", "seconds": 6.819, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/23", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-23", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.48, "w": 0.25, "x": 0.68, "y": 0.22 }, "kind": "chart", "text": "Reduction in ROS1 G2032R Allele: Complete clearance in 7/7 patients", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:02.167+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6f1e8b84-b871-47c0-9258-aa7fe04c81fd", "parentComponentId": null }, { "bbox": { "h": 0.48, "w": 0.32, "x": 0.35, "y": 0.22 }, "kind": "chart", "text": "Reduction in Tumor Burden in Cancers with ROS1 G2032R", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:02.167+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4e758fe4-cd4f-4430-83e9-53ba0c1da132", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.85, "x": 0.07, "y": 0.84 }, "kind": "disclaimer", "text": "Data as of 13 Sep 22, for response-evaluable patients with NSCLC treated by 01 Sep 2022. Source: Drilon A. et al., EORTC-NCI-AACR 2022.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:02.167+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1ea95552-c490-49a4-9267-c5e0fa5f91e8", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.58, "x": 0.35, "y": 0.74 }, "kind": "legend", "text": "Each unique color indicates data from the same patient across both figures; PD (due to new lesions); Prior treatments include repotrectinib", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:02.167+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "472148d7-8dcc-4951-87e4-043f2e634b5a", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.28, "x": 0.07, "y": 0.26 }, "kind": "list", "text": "Subgroup with known ROS1 G2032R resistance mutation: ORR: 78% (7/9); 100% (9/9) with tumor shrinkage. One patient with ROS1 D2033N with ongoing PR (-40%) pending confirmation.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:02.167+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3fa0aa4b-bc0e-43e5-8249-10d3a58468b6", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.85, "x": 0.07, "y": 0.06 }, "kind": "title", "text": "ROS1 Resistance Mutations | NVL-520 Induced Rapid Responses in TKI-Resistant Patients", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:02.167+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e000905a-5d23-4ce1-ba47-bb96e21ebe9e", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "2x2 matrix", "slug": "matrix-2x2", "status": "active", "bestFor": null, "canonId": "019dd9e1-50ab-72d1-8afb-3ab0a38e32a8", "version": 1, "bodyDocId": null, "description": "BCG matrix, importance/urgency, any axes-and-quadrants frame.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "72ae47d2-6e30-4886-abcc-72ad7bc60efd", "evidence": "table/data: Dose level and prior therapy history table", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:31:02.853941+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 23, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 24, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 19, "name": "Traction", "beatId": "fe8c99d1-59ae-4350-9a12-ffd07cd22e0a", "matchId": "94029b68-a5c1-4a28-8d68-beb9720b9a6d", "beatType": null, "evidence": "Preliminary efficacy and safety data are presented.", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 24, "from": 19, "loop": { "name": "14_day_in_life", "slug": "14-day-in-life", "status": "active", "bestFor": "Product demos, UX reviews, investor pitches focusing on pain points", "canonId": "019dd956-6b65-707f-9b14-89beaaab81fa", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The User's Struggle -> The Intervention (Your Solution) -> The Resolved State", "description": "Humanize abstract data by walking through a single user's struggle and resolution", "familyLabel": null }, "matchId": "a5849bfd-1f57-46db-8128-2b35af72eb66", "evidence": "Preliminary efficacy data are presented.", "position": 1, "objective": "How do patients benefit from Nuvalent's therapies?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:37:21.795555+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 24, "type": "evidence", "title": "Includes patient case study images and clinical trial metrics.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "balanced", "densityScore": 45, "componentCount": 4, "textChars": 403, "nDataPoints": 3, "notes": "Includes patient case study images and clinical trial metrics.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:33:57.797+00", "seconds": 2.413, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/24", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-24", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.85, "x": 0.07, "y": 0.8 }, "kind": "disclaimer", "text": "Data as of 13 Sep 22... Intracranial response in 65-year-old female...", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:57.797+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c1169b5a-82ef-4eba-9267-c4666209eb05", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.5, "x": 0.43, "y": 0.2 }, "kind": "image", "text": "MRI scan series showing baseline, 4 weeks, and 8 weeks", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:57.797+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "aadf414e-634d-4a36-b896-ca33f9358d3f", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.35, "x": 0.07, "y": 0.25 }, "kind": "list", "text": "Intracranial PR in 3/3 patients with measurable (>10 mm) CNS metastases; ORR of 73% (8/11) in response-evaluable patients with history of CNS metastases; No CNS progression observed in any of the 35 treated patients", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:57.797+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ca0c907a-6939-4ad7-b39a-71b45b638a82", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.07, "y": 0.11 }, "kind": "title", "text": "CNS Activity | NVL-520 Induced Responses in Intracranial Lesions", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:57.797+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "17d2a3e6-d577-4a4b-a152-dbcdee825f02", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 24, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 19, "name": "Traction", "beatId": "fe8c99d1-59ae-4350-9a12-ffd07cd22e0a", "matchId": "94029b68-a5c1-4a28-8d68-beb9720b9a6d", "beatType": null, "evidence": "Preliminary efficacy and safety data are presented.", "position": 3, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 24, "from": 19, "loop": { "name": "14_day_in_life", "slug": "14-day-in-life", "status": "active", "bestFor": "Product demos, UX reviews, investor pitches focusing on pain points", "canonId": "019dd956-6b65-707f-9b14-89beaaab81fa", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The User's Struggle -> The Intervention (Your Solution) -> The Resolved State", "description": "Humanize abstract data by walking through a single user's struggle and resolution", "familyLabel": null }, "matchId": "a5849bfd-1f57-46db-8128-2b35af72eb66", "evidence": "Preliminary efficacy data are presented.", "position": 1, "objective": "How do patients benefit from Nuvalent's therapies?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:37:21.795555+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 25, "type": "evidence", "title": "Includes a timeline of treatments leading up to NVL-520 and radiological evidence of response.", "function": "illustrate_case", "rawType": "testimonial", "block": null, "metadata": { "slideType": "testimonial", "slideTypeCanon": { "name": "Testimonial", "slug": "testimonial", "status": "active", "canonId": "019de52d-0a2d-7782-8a48-7e84df92cc97", "version": 1, "description": null }, "function": "illustrate_case", "functionCanon": { "name": "Illustrate case", "slug": "illustrate_case", "status": "active", "canonId": "019de52d-13b4-772c-bb73-1873612a7463", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 77, "componentCount": 6, "textChars": 1290, "nDataPoints": 6, "notes": "Includes a timeline of treatments leading up to NVL-520 and radiological evidence of response.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:33:59.289+00", "seconds": 3.838, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/25", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-25", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.58, "w": 0.53, "x": 0.43, "y": 0.21 }, "kind": "image", "text": "CT and MRI scans at Baseline, 4 weeks, and 16 weeks", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:59.289+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d23452b0-e1b6-4cef-91e5-ccdf0c549466", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.32, "x": 0.1, "y": 0.55 }, "kind": "list", "text": "PR (-38% by RECIST 1.1) at 4 weeks: right occipital lobe metastasis contraction, decrease in several liver/lung metastases; Further disease regression (-58%) at 16 weeks, near-complete resolution of brain lesion; Treatment well-tolerated; Ongoing response at 5.3 months", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:59.289+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bbea3cb4-179d-41a4-8849-47cee592e557", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.35, "x": 0.07, "y": 0.22 }, "kind": "list", "text": "Diagnosis: EZR-ROS1 fusion NSCLC; Entrectinib (~9 months, ROS1 G2032R found on PD); Repotrectinib (~8 weeks); Platinum-based chemo + bevacizumab + entrectinib (Administered for PD, ~8 weeks, primary PD, G2032R still present); NVL-520 (50 mg QD)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Timeline item", "slug": "timeline-item", "status": "active", "canonId": "019de52c-fd0e-74ce-9443-440fbd8c23b4", "version": 1, "description": null }, "framework": null }, "subkind": "timeline-item", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:59.289+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b43c8017-0775-422b-a82a-e929ebe88e85", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.53, "x": 0.43, "y": 0.79 }, "kind": "paragraph", "text": "Upper panel: CT indicating segment 5/6 and 3 liver metastases with continuous regression over the course of treatment. Lower panel: MRI demonstrating right occipital lobe metastasis that decreased in size at week 4 and became barely appreciable at week 16.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:59.289+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0a8952cb-8fe5-471e-9580-c04c95e07403", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.89, "x": 0.07, "y": 0.88 }, "kind": "source-note", "text": "Data as of 13 Sep 22. CT, computed tomography; MRI, magnetic resonance imagine; NSCLC, non-small cell lung cancer; PD, Progressive Disease; QD, once daily; RECIST 1.1, Response Evaluation Criteria in Solid Tumours version 1.1; TKI, tyrosine kinase inhibitor. Images courtesy of Alexander Drilon, Memorial Sloan Kettering Cancer Center. Source: Drilon A. et al., EORTC-NCI-AACR 2022.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:59.289+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3f2920a6-a4d2-4f85-b9f2-185cc8cc24ea", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.85, "x": 0.07, "y": 0.06 }, "kind": "title", "text": "Case Study | Intracranial and Extracranial Activity in TKI-Refractory ROS1 G2032R+ NSCLC", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:59.289+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "98351def-bb0e-4121-998e-611422cb7d02", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 26, "type": "resolution", "title": "Slide 26 of a clinical presentation.", "function": "summarize", "rawType": "key_takeaways", "block": null, "metadata": { "slideType": "key_takeaways", "slideTypeCanon": { "name": "Key takeaways", "slug": "key_takeaways", "status": "active", "canonId": "019de52d-06e7-7674-a891-9f7de3b11b6d", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "dense", "densityScore": 69, "componentCount": 6, "textChars": 1015, "nDataPoints": 0, "notes": "Slide 26 of a clinical presentation.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:34:02.828+00", "seconds": 7.259, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/26", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-26", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.848, "x": 0.076, "y": 0.55 }, "kind": "list", "text": "This preliminary dataset indicates encouraging clinical activity in a heavily pre-treated population, with responses observed in patients with and without ROS1 G2032R resistance, prior progression, and brain metastases.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:02.828+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "49eca47c-7571-4a60-ad3c-11467ba4f83c", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.848, "x": 0.076, "y": 0.83 }, "kind": "list", "text": "Phase 1 ongoing to further understand the safety profile, PK, and preliminary efficacy, and determine the RP2D", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:02.828+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "91180c9d-2b1d-4148-aa15-41405c655535", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.848, "x": 0.076, "y": 0.275 }, "kind": "list", "text": "In the ongoing ARROS-1 Phase 1 dose-escalation, a wide dose range resulted in exposures exceeding predicted efficacy thresholds without indication of off-target toxicity. NVL-520 has been well tolerated with no DLTs. No dose reductions or discontinuations.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:02.828+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a2fd0e3e-ec02-4884-bc97-ee4a4434aae6", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.65, "x": 0.076, "y": 0.88 }, "kind": "source-note", "text": "CNS, central nervous system; DLTs, dose-limiting toxicities; NSCLC, non-small cell lung cancer; PK, pharmacokinetics; RP2D, recommended phase 2 dose. Source: Drilon A. et al., EORTC-NCI-AACR 2022.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:02.828+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f6123819-fd06-4d18-9876-488d3e84cc43", "parentComponentId": null }, { "bbox": { "h": 0.065, "w": 0.848, "x": 0.076, "y": 0.145 }, "kind": "title", "text": "NVL-520 is a brain-penetrant, selective inhibitor of ROS1 and ROS1 resistance mutations with the potential to minimize TRK-related CNS adverse events while providing CNS antitumor activity", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:02.828+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1c6becd6-36de-4393-bedd-ddab0172c310", "parentComponentId": null }, { "bbox": { "h": 0.025, "w": 0.464, "x": 0.076, "y": 0.105 }, "kind": "title", "text": "CONCLUSIONS – PRELIMINARY DOSE ESCALATION DATA", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:02.828+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "30543607-35b7-46af-a288-82138750f521", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 27, "type": "resolution", "title": "The slide uses a list of icons to represent key features of the drug candidate.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 41, "componentCount": 4, "textChars": 342, "nDataPoints": 1, "notes": "The slide uses a list of icons to represent key features of the drug candidate.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:34:01.273+00", "seconds": 5.379, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/27", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-27", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.55, "w": 0.06, "x": 0.512, "y": 0.25 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Icon grid", "slug": "icon-grid", "status": "active", "canonId": "019de52c-fdfe-749d-9990-1db465a3eed4", "version": 1, "description": null }, "framework": null }, "subkind": "icon-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:01.273+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a5f20963-85cf-47a3-9a57-b4281ae566b6", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.45, "x": 0.512, "y": 0.25 }, "kind": "list", "text": "Active against wild-type ALK fusions\nActive against treatment-emergent ALK G1202R single and compound resistance mutations\nBrain penetrant (~30-40% of patients with ALK-positive NSCLC present with brain metastases)\nTRK sparing to minimize CNS adverse events", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:01.273+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9e1dfea7-598e-4650-b9bc-237395f92159", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.25, "x": 0.512, "y": 0.188 }, "kind": "title", "text": "TARGET PRODUCT PROFILE:", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:01.273+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "aaa5d63c-3ef7-4ad3-8c7d-181442e20618", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.33, "x": 0.106, "y": 0.318 }, "kind": "title", "text": "NVL-655 for ALK-Positive Advanced NSCLC and Other Solid Tumors", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:01.273+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ddd79277-405d-4f2a-b756-18cf41d56b77", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 28, "type": "resolution", "title": "The table highlights the progression of resistance mutations and the increasing prevalence of CNS disease as patients move through lines of therapy.", "function": "size_opportunity", "rawType": "market_sizing", "block": null, "metadata": { "slideType": "market_sizing", "slideTypeCanon": { "name": "Market sizing", "slug": "market_sizing", "status": "active", "canonId": "019de52d-08c8-756c-8664-733b73a7ee7b", "version": 1, "description": null }, "function": "size_opportunity", "functionCanon": { "name": "Size opportunity", "slug": "size_opportunity", "status": "active", "canonId": "019de52d-147b-7568-8828-a74a27697618", "version": 1, "description": null }, "density": "balanced", "densityScore": 48, "componentCount": 4, "textChars": 446, "nDataPoints": 6, "notes": "The table highlights the progression of resistance mutations and the increasing prevalence of CNS disease as patients move through lines of therapy.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:33:58.52+00", "seconds": 2.57, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/28", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-28", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.03, "w": 0.6, "x": 0.07, "y": 0.9 }, "kind": "source-note", "text": "Sources: Ou and Zhu Lung Cancer 2019; Kris et. al. JAMA 2014; Shaw and Engelman J Clin Onc 2013; Noé et. al. J Thor Onc 2019; Peters et. al. NEJM 2017; Shaw et. al. Lancet Onc 2017; Dagogo-Jack et. al. Clin Cancer Res 2019", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:58.52+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "28a1fa76-b9fb-46ee-8c2f-db96725f4174", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.86, "x": 0.07, "y": 0.265 }, "kind": "table", "text": "Table showing lines of therapy, sub-populations, incidence, CNS disease, and standard of care.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:58.52+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e3a31e25-4e46-46a0-a0fc-9f901b4bd4a6", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.65, "x": 0.07, "y": 0.18 }, "kind": "title", "text": "Emerging Resistance Mutations and Increasing CNS Involvement Limit Utility of Approved Therapies", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:58.52+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2e491c0a-9677-411c-a576-5e88ba25591a", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.45, "x": 0.07, "y": 0.11 }, "kind": "title", "text": "ALK-Positive NSCLC Market Overview", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:58.52+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "33e7b87a-3733-4ba4-80bd-5f5f0d577d97", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 29, "type": "setup", "title": "The table uses a green/white color coding to highlight positive attributes of NVL-655 compared to competitors.", "function": "compare_peers", "rawType": "competitive_analysis", "block": null, "metadata": { "slideType": "competitive_analysis", "slideTypeCanon": { "name": "Competitive analysis", "slug": "competitive_analysis", "status": "active", "canonId": "019de52d-093e-776b-94c6-c1573f5f1a31", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "balanced", "densityScore": 36, "componentCount": 4, "textChars": 355, "nDataPoints": 0, "notes": "The table uses a green/white color coding to highlight positive attributes of NVL-655 compared to competitors.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:33:59.66+00", "seconds": 3.386, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/29", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-29", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.06, "w": 0.85, "x": 0.077, "y": 0.845 }, "kind": "disclaimer", "text": "No head-to-head clinical studies have been conducted for currently approved or investigational therapies versus NVL-655. Clinical investigation of NVL-655 is ongoing.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:59.66+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "87d3b3a2-9e27-4e00-8a1c-c254e1659ca2", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.85, "x": 0.075, "y": 0.265 }, "kind": "table", "text": "Comparison matrix of NVL-655 vs Crizotinib, Ceritinib, Alectinib, Brigatinib, Lorlatinib across 5 activity categories.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:59.66+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "53fb4dcd-a982-40da-9aff-af788a0af1dc", "parentComponentId": null }, { "bbox": { "h": 0.025, "w": 0.45, "x": 0.077, "y": 0.188 }, "kind": "title", "text": "Differentiated Product Candidate for ALK-positive NSCLC patients", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:59.66+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "941b5935-6587-4679-9478-a1fdc3eee9d3", "parentComponentId": null }, { "bbox": { "h": 0.055, "w": 0.145, "x": 0.077, "y": 0.115 }, "kind": "title", "text": "NVL-655", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:59.66+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "808649e2-8790-4780-98a3-a13e627f8772", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "NxN matrix", "slug": "matrix-nxn", "status": "active", "bestFor": null, "canonId": "019de52d-2313-71fa-bb45-a7d1a4aae23a", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "c8a6a78f-3a24-448c-8530-e748747e6e8c", "evidence": "table/data: Comparison matrix of NVL-655 vs Crizotinib, Ceritinib, Alectinib, Brigatinib, Lorlatinib across 5 activity categories", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:31:03.073769+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 29, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "f0c8731e-a666-42e2-b4f6-eca59f65b937", "evidence": "Table comparing product features against competitors", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:33:59.66+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 29, "frameworkName": "comparison-frame" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 30, "type": "resolution", "title": "The slide uses three distinct chart types to demonstrate efficacy, pharmacokinetics, and selectivity.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 63, "componentCount": 5, "textChars": 555, "nDataPoints": 25, "notes": "The slide uses three distinct chart types to demonstrate efficacy, pharmacokinetics, and selectivity.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:33:59.919+00", "seconds": 3.228, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/30", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-30", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.55, "w": 0.35, "x": 0.58, "y": 0.22 }, "kind": "chart", "text": "AVOIDING TRK INHIBITION", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Grouped bar chart", "slug": "bar-grouped", "status": "active", "canonId": "019de52c-ff3b-751e-a8ff-f21ff11097b1", "version": 1, "description": null }, "framework": null }, "subkind": "bar-grouped", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:59.919+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "600856f8-08fa-4799-8d7e-a9decc00f0a5", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.15, "x": 0.41, "y": 0.22 }, "kind": "chart", "text": "BRAIN PENETRANCE", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:59.919+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "271d0017-956e-4ee6-b4bb-49acdf32183e", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.32, "x": 0.07, "y": 0.22 }, "kind": "chart", "text": "ACTIVITY AGAINST ALK WILD-TYPE AND MUTANTS", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Dot plot", "slug": "dot", "status": "active", "canonId": "019de52d-0235-738b-bd2b-78f8e24d7cb0", "version": 1, "description": null }, "framework": null }, "subkind": "dot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:59.919+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1718eaa6-279f-4414-8724-b369b1ab4ae4", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.75, "x": 0.07, "y": 0.88 }, "kind": "disclaimer", "text": "IC50, half-maximal inhibitory concentration; PO, orally; pTRK, BDNF-stimulated TRKB phosphorylation. Head-to-head clinical studies comparing NVL-655 with currently approved or investigational therapies have not been conducted. Above data from preclinical studies. Sources: Mizuta, H. et al., WCLC 2022; Pelish, H.E. et al., AACR 2021; Data on file.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:59.919+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2645a316-e9a9-4e09-b032-6b138eaeba99", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.85, "x": 0.07, "y": 0.05 }, "kind": "title", "text": "Preclinical | NVL-655 is a Brain Penetrant, ALK-Selective Inhibitor with the Potential to Avoid TRK-Related CNS Adverse Events", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:33:59.919+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e573b2e8-c4b7-4cdf-b3c4-339ce335773e", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 31, "type": "evidence", "title": "The slide compares vehicle control against NVL-655 treatment in both bar chart (multiple models) and line chart (PDX model) formats.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 66, "componentCount": 5, "textChars": 672, "nDataPoints": 20, "notes": "The slide compares vehicle control against NVL-655 treatment in both bar chart (multiple models) and line chart (PDX model) formats.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:34:00.462+00", "seconds": 2.993, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/31", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-31", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.42, "x": 0.08, "y": 0.22 }, "kind": "chart", "text": "In vivo activity, ALK wild-type & mutants (single and compound)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.462+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5854ee11-20ed-4cc2-90f1-58d3fa941c61", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.42, "x": 0.52, "y": 0.22 }, "kind": "chart", "text": "In vivo activity, patient-derived xenograft (PDX) ALK+ NSCLC with G1202R/L1196M compound mutation", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.462+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "54ad7928-3a00-418c-a975-13f02729e9e0", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.45, "x": 0.49, "y": 0.75 }, "kind": "list", "text": "MGH953-7 model derived from a patient with ALK fusion-positive NSCLC; Progressed on sequential treatments with crizotinib, alectinib, and lorlatinib; Harbors EML4-ALK v3 G1202R/L1196M", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.462+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a1b7ebe8-6a96-4403-b90f-7dff302a05b6", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.85, "x": 0.07, "y": 0.9 }, "kind": "source-note", "text": "BID, twice daily; Sources: Pelish H.E. et al., AACR 2021; Tangpeerachaikul A. et al., EORTC-NCI-AACR 2021; Tangpeerachaikul A. et al., AACR 2022; Mizuta H. et al., WCLC 2022; Fujino T. et al., EORTC-NCI-AACR 2022.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.462+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "78b82507-302f-4c59-84ae-3c522050b6e5", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.85, "x": 0.07, "y": 0.06 }, "kind": "title", "text": "Preclinical | NVL-655 Induced Tumor Regression Across Models of Diverse ALK Single and Compound Resistance Mutations", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.462+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7972934e-8a28-467e-8ce2-c2cf09ae3ff6", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Chartjunk Elimination", "slug": "chartjunk-elimination", "status": "active", "bestFor": null, "canonId": "019dd956-b49e-7453-ab01-b60f338eeda1", "version": 1, "bodyDocId": null, "description": "Remove decorative elements that don't convey data: 3D effects, shadows, unnecessary gridlines", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "d7c7427f-9761-4199-a1d4-53563230db2f", "evidence": "chart/line: In vivo activity, patient-derived xenograft (PDX) ALK+ NSCLC with G1202R/L1196M compound mutation", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:31:16.341949+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 31, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 32, "type": "analysis", "title": "The slide outlines a clinical trial structure with a dose-escalation phase and specific patient cohorts for Phase 2.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "balanced", "densityScore": 40, "componentCount": 4, "textChars": 432, "nDataPoints": 0, "notes": "The slide outlines a clinical trial structure with a dose-escalation phase and specific patient cohorts for Phase 2.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:34:00.615+00", "seconds": 3.121, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/32", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-32", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.06, "w": 0.43, "x": 0.5, "y": 0.82 }, "kind": "callout", "text": "Preliminary data update from dose-escalation planned in 4Q 2023", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.615+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "29696e79-f2e8-4e40-9442-44d34957f91f", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.45, "x": 0.07, "y": 0.81 }, "kind": "disclaimer", "text": "Patients with ALK fusion-positive NSCLC must have previously received ≥1 ALK TKI... Excluding investigational agents... Exploratory cohort...", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.615+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "81a635b4-1d0d-4d1a-a872-eb9edf0fd9f7", "parentComponentId": null }, { "bbox": { "h": 0.62, "w": 0.86, "x": 0.07, "y": 0.24 }, "kind": "table", "text": "Phase 1 and Phase 2 cohort definitions including tumor type, prior ALK TKI, and prior chemo/IO lines.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.615+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ad4c5e27-07ab-4b2e-b375-67e1fe0e826d", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.85, "x": 0.07, "y": 0.06 }, "kind": "title", "text": "ALKove-1 First-in-Human Phase 1/2 Clinical Trial of NVL-655 in Advanced ALK-Positive NSCLC and Other Solid Tumors (NCT05384626)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.615+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "306c7002-270d-4b83-947a-53214fb27bc8", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "636c3723-63f1-46a5-a24a-078a3ba524b6", "evidence": "table/data: Phase 1 and Phase 2 cohort definitions including tumor type, prior ALK TKI, and prior chemo/IO lines.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:31:16.421926+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 32, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 33, "type": "setup", "title": "The slide outlines the key therapeutic advantages of the drug candidate NVL-330.", "function": "present_solution", "rawType": "product_demo", "block": null, "metadata": { "slideType": "product_demo", "slideTypeCanon": { "name": "Product demo", "slug": "product_demo", "status": "active", "canonId": "019de52d-0f06-7288-84f2-7568c1020fce", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 54, "componentCount": 6, "textChars": 288, "nDataPoints": 1, "notes": "The slide outlines the key therapeutic advantages of the drug candidate NVL-330.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:34:00.614+00", "seconds": 3.109, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/33", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-33", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.41, "w": 0.058, "x": 0.512, "y": 0.335 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Icon grid", "slug": "icon-grid", "status": "active", "canonId": "019de52c-fdfe-749d-9990-1db465a3eed4", "version": 1, "description": null }, "framework": null }, "subkind": "icon-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.614+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "11b7514f-9406-4935-a23a-5196487122aa", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.35, "x": 0.586, "y": 0.495 }, "kind": "list", "text": "EGFR sparing. Related adverse events include skin rash and diarrhea", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.614+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c0ad76c8-46af-48c8-81dc-4377d6be7900", "parentComponentId": null }, { "bbox": { "h": 0.025, "w": 0.25, "x": 0.586, "y": 0.362 }, "kind": "list", "text": "Active against HER2 and HER2ex20", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.614+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e8ec2f36-1ec6-422b-ae55-3a4ec80abca9", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.35, "x": 0.586, "y": 0.682 }, "kind": "list", "text": "Brain penetrant. ~20% of patients with HER2-positive NSCLC present with brain metastases", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.614+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ef1d6a6e-53a6-4c5c-96a3-f66a12c3e61d", "parentComponentId": null }, { "bbox": { "h": 0.025, "w": 0.25, "x": 0.512, "y": 0.233 }, "kind": "title", "text": "TARGET PRODUCT PROFILE:", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.614+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4fb9b094-b14a-4528-a647-6992931f6c1c", "parentComponentId": null }, { "bbox": { "h": 0.14, "w": 0.35, "x": 0.106, "y": 0.358 }, "kind": "title", "text": "NVL-330 for Malignancies Driven by HER2 Exon 20 Insertion Mutations (HER2ex20)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.614+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "68e96bac-df96-4bf4-959d-32f58cea4816", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "afa0a69f-5771-4550-9bfc-20d26e12455a", "evidence": "list/bullet: Brain penetrant. ~20% of patients with HER2-positive NSCLC present with brain metastases", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:31:16.503242+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 33, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 34, "type": "resolution", "title": "Includes three distinct charts: a dot plot for IC50, a bar chart for selectivity index, and a bar chart for brain penetrance.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 60, "componentCount": 5, "textChars": 489, "nDataPoints": 15, "notes": "Includes three distinct charts: a dot plot for IC50, a bar chart for selectivity index, and a bar chart for brain penetrance.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:34:00.616+00", "seconds": 3.065, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/34", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-34", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.21, "x": 0.72, "y": 0.22 }, "kind": "chart", "text": "BRAIN PENETRANCE", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.616+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "356c1f66-3a42-4912-9b1b-67c273925006", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.31, "x": 0.39, "y": 0.22 }, "kind": "chart", "text": "AVOIDING EGFR INHIBITION", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.616+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f45bcfee-e2e4-420e-841a-3b9516dd66a3", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.31, "x": 0.07, "y": 0.22 }, "kind": "chart", "text": "IN VITRO ACTIVITY, HER2 AND HER2ex20", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Dot plot", "slug": "dot", "status": "active", "canonId": "019de52d-0235-738b-bd2b-78f8e24d7cb0", "version": 1, "description": null }, "framework": null }, "subkind": "dot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.616+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "452b10c7-5a84-40f2-b5ff-f54b43b723d6", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.86, "x": 0.07, "y": 0.88 }, "kind": "disclaimer", "text": "IC50, half-maximal inhibitory concentration; PO, orally; Head-to-head clinical studies comparing NVL-330 with currently approved or investigational therapies have not been conducted. Above data from preclinical studies Source: Andrews K.L. et al., EORTC-NCI-AACR 2022.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.616+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5fed2f1d-590d-4fd9-991b-547e7ff6596f", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.86, "x": 0.07, "y": 0.06 }, "kind": "title", "text": "Preclinical | NVL-330 is a Brain Penetrant, HER2ex20-Selective Kinase Inhibitor with Potential to Avoid Adverse Events Related to EGFR Inhibition", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.616+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fd0696c5-3322-4ec0-8197-39886d4d8b8b", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Chart Selection Guide", "slug": "chart-selection-guide", "status": "active", "bestFor": null, "canonId": "019dd956-b1a0-700b-ba17-0e16c4d5bcae", "version": 1, "bodyDocId": null, "description": "Choosing the right chart type for your data and message", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "862fe5bb-cfec-4ff1-917a-75f5fe2aa618", "evidence": "chart/dot: IN VITRO ACTIVITY, HER2 AND HER2ex20", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:31:16.585296+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 34, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 35, "type": "setup", "function": "transition", "rawType": "section_divider", "block": null, "metadata": { "slideType": "section_divider", "slideTypeCanon": { "name": "Section divider", "slug": "section_divider", "status": "active", "canonId": "019de52d-066a-7402-9554-6ae504999041", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 4, "componentCount": 2, "textChars": 26, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:34:00.059+00", "seconds": 2.466, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/35", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-35", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.192, "x": 0.073, "y": 0.75 }, "kind": "image", "text": "Nuvalent", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.059+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ee9e0cc1-fee6-4e93-8610-17377da199ff", "parentComponentId": null }, { "bbox": { "h": 0.083, "w": 0.443, "x": 0.076, "y": 0.458 }, "kind": "title", "text": "Pipeline Expansion", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.059+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0b6f236b-e336-451a-b5dd-e8c0432f69a9", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Section divider", "slug": "section-divider", "status": "active", "bestFor": null, "canonId": "019dd9e1-4c66-707d-8d1f-6e14547134c7", "version": 1, "bodyDocId": null, "description": "A transitional slide marking the start of a new section.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "da8f0b11-61df-4422-bf3f-63a6e16bc192", "evidence": "title/headline: Pipeline Expansion", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:31:16.668071+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 35, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 36, "type": "appendix", "title": "The slide uses a cascading hexagonal process flow to illustrate the methodology.", "function": "present_framework", "rawType": "other", "block": null, "metadata": { "slideType": "other", "slideTypeCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43", "version": 1, "description": null }, "function": "present_framework", "functionCanon": { "name": "Present framework", "slug": "present_framework", "status": "active", "canonId": "019de52d-1403-7667-9100-d2ac6709f750", "version": 1, "description": null }, "density": "dense", "densityScore": 66, "componentCount": 6, "textChars": 723, "nDataPoints": 0, "notes": "The slide uses a cascading hexagonal process flow to illustrate the methodology.", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:34:01.125+00", "seconds": 3.407, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/36", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-36", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.75, "w": 0.35, "x": 0.239, "y": 0.095 }, "kind": "diagram", "text": "Three-step process flow using hexagonal icons", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:01.125+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "76a8014e-2417-4f17-b2b9-c414e1cde14e", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.3, "x": 0.65, "y": 0.68 }, "kind": "list", "text": "Disciplined Program Advancement: Well defined selection criteria; Focused resource deployment on opportunities with potential for immediate impact", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:01.125+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2bd2602e-52e6-498e-bcab-507ef1d7a000", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.4, "x": 0.54, "y": 0.36 }, "kind": "list", "text": "Rigorous Target Selection: Combine clinical insights with internal expertise in chemistry and structure-based drug design and development; Prioritize opportunities with an aim to maximize patient impact through more selective kinase inhibitor design", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:01.125+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3f4977c8-caa6-404d-b356-d2948c4022da", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.4, "x": 0.45, "y": 0.12 }, "kind": "list", "text": "Close Partnership with Physician-Scientists: Characterize emerging medical needs for patients; Refine understanding of safety events observed with currently available multi-kinase inhibitors", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:01.125+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e3721da8-c674-4546-86e5-df1f1d14ded9", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.25, "x": 0.07, "y": 0.5 }, "kind": "title", "text": "Rigorous Target Selection and Disciplined Advancement of Discovery Programs", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:01.125+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d51363b1-d6bf-4842-a9bf-8a3453299460", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.2, "x": 0.07, "y": 0.4 }, "kind": "title", "text": "Pipeline Expansion", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:01.125+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cbbaf5be-8dc1-4aae-bfc9-549a11cc0cac", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Process flow", "slug": "process-flow", "status": "active", "bestFor": null, "canonId": "019dd9e1-4dca-76bc-8135-401836a1c4c0", "version": 1, "bodyDocId": null, "description": "Workflow, steps, sequential diagram.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "530f04d4-45df-42b8-b276-222195d06058", "evidence": "diagram/process: Three-step process flow using hexagonal icons", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:31:16.757389+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 36, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "fd200d40-7050-4b6b-9e63-480796e4e920", "evidence": "Sequential flow of three strategic steps", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:34:01.125+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 36, "frameworkName": "process" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 37, "type": "resolution", "title": "The slide uses a timeline-style layout to track drug development progress from discovery through clinical phases.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "balanced", "densityScore": 42, "componentCount": 5, "textChars": 308, "nDataPoints": 0, "notes": "The slide uses a timeline-style layout to track drug development progress from discovery through clinical phases.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:34:00.792+00", "seconds": 2.833, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/37", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-37", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": null, "kind": "framework", "text": "Pipeline chart showing drug development stages", "attrs": null, "canon": { "kind": { "name": "Framework", "slug": "framework", "status": "active", "canonId": "019de52c-fa18-77c6-b10a-ccb8277ac0fa", "version": 1, "description": "Named conceptual framework instance." }, "tool": null, "subkind": { "name": "Framework instance", "slug": "instance", "status": "active", "canonId": "019de52d-05a2-72af-be0b-7edc60708a03", "version": 1, "description": null }, "framework": null }, "subkind": "instance", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.792+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "767a3c8c-f5a1-4fea-b51f-e69935261643", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.1, "x": 0.85, "y": 0.92 }, "kind": "image", "text": "Nuvalent logo", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.792+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "63767893-eda0-4c0e-af00-6b65a471b743", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.8, "x": 0.07, "y": 0.18 }, "kind": "subtitle", "text": "Advancing parallel lead programs in ROS1-positive and ALK-positive NSCLC, and multiple early-stage discovery programs", "attrs": null, "canon": { "kind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "82d821ee-2793-42e7-8f16-c6131385a3ce", "version": 1, "description": "Header-zone supporting text near the title (= ex body.description with bbox)." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.792+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "39663047-ac95-42c7-b6b5-a26492a09567", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.9, "x": 0.05, "y": 0.25 }, "kind": "table", "text": "Pipeline table with columns for Indication, Candidate, Mutations, Status, Milestones, and Rights", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.792+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fc498553-6e41-49e9-9155-1128e97d1a80", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.4, "x": 0.07, "y": 0.1 }, "kind": "title", "text": "Nuvalent Pipeline – Ongoing Programs", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.792+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "13d9329c-3773-40e1-96aa-39cb6680598e", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "4f47e245-8219-4fd6-9590-7fc6d03b6a9e", "evidence": "The slide uses a horizontal bar structure to represent progress through clinical phases.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:34:00.792+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 37, "frameworkName": "gantt-chart" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 38, "type": "resolution", "title": "Includes a molecular structure visualization.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 68, "componentCount": 6, "textChars": 876, "nDataPoints": 0, "notes": "Includes a molecular structure visualization.", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:34:00.847+00", "seconds": 2.88, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/38", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-38", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.75, "w": 0.28, "x": 0.68, "y": 0.15 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.847+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c4df02ec-bfa5-4213-bf51-67efcef0922b", "parentComponentId": null }, { "bbox": { "h": 0.22, "w": 0.55, "x": 0.07, "y": 0.52 }, "kind": "list", "text": "Parallel lead clinical programs in ROS1-positive and ALK-positive NSCLC: 2023 operational focus on advancement of concurrent Phase 1/2 clinical trials. Preliminary data from dose-escalation portion of Phase 1/2 ARROS-1 study presented at EORTC-NCI-AACR 2022. Preliminary data update from ALKOVE-1 dose-escalation planned at a medical meeting in 4Q’23.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.847+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1ba4e4be-e332-43fa-9de3-56108df2bc52", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.55, "x": 0.07, "y": 0.33 }, "kind": "list", "text": "Innovative molecular structures with the potential to overcome the dual challenges of kinase resistance and selectivity in the CNS and in the periphery. Potential for differentiated inhibition of proven kinase targets with opportunities for clinical utility earlier in the treatment paradigm.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.847+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "35ab5301-becf-45dd-97a5-7d03aedd936c", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.35, "x": 0.07, "y": 0.89 }, "kind": "paragraph", "text": "Expected cash runway into second half of 2025", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.847+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2282a9ce-8460-4429-8e81-6a9ad8c51aee", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.55, "x": 0.07, "y": 0.79 }, "kind": "paragraph", "text": "Robust development pipeline leveraging established approach: NVL-330 selected as new development candidate for HER2ex20-positive tumors", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.847+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fb263524-a15d-4e21-a345-32108202a919", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.45, "x": 0.07, "y": 0.23 }, "kind": "title", "text": "PRECISELY Targeted Therapies for patients with cancer", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:00.847+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "acf9829e-62bb-4b33-b4b8-b348e11fce8c", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "72124841-56e3-4996-9661-bdcfd5900ab5", "evidence": "paragraph/paragraph: Robust development pipeline leveraging established approach: NVL-330 selected as new development candidate for HER2ex20-positive tumors", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:31:16.879035+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 38, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 39, "type": "setup", "function": "front_matter", "rawType": "cover", "block": null, "metadata": { "slideType": "cover", "slideTypeCanon": { "name": "Cover", "slug": "cover", "status": "active", "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "sparse", "densityScore": 21, "componentCount": 4, "textChars": 99, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:34:03.904+00", "seconds": 5.718, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/39", "deck": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e", "deckAnchor": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-39", "deckJson": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json" }, "components": [ { "bbox": { "h": 0.772, "w": 0.268, "x": 0.708, "y": 0.164 }, "kind": "image", "text": "3D molecular structure", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:03.904+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fd1cf076-b765-4b9c-8fb7-5e131829590b", "parentComponentId": null }, { "bbox": { "h": 0.223, "w": 0.332, "x": 0.334, "y": 0.388 }, "kind": "image", "text": "Nuvalent", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:03.904+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "751c39bc-58e1-4f22-ab5e-893df67623e4", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.16, "x": 0.42, "y": 0.556 }, "kind": "paragraph", "text": "www.nuvalent.com", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:03.904+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3170c0bc-0ca7-4bc6-923e-d3ac391354fc", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.34, "x": 0.33, "y": 0.848 }, "kind": "title", "text": "PRECISELY Targeted Therapies for patients with cancer", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:34:03.904+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0e5b2814-b10f-4609-9eee-3e96e7b55ab4", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "4dac34b4-0e3d-40b2-9004-b8bc4a443da7", "evidence": "title/action-title: PRECISELY Targeted Therapies for patients with cancer", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:31:16.960182+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 39, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true } ], "arcBeats": [ { "from": 7, "to": 7, "label": "Problem", "description": "The problem of kinase resistance is clearly stated." }, { "from": 6, "to": 6, "label": "Solution", "description": "The solution of precisely targeted therapies is introduced." }, { "from": 10, "to": 10, "label": "Market Sizing", "description": "The market for ROS1-positive NSCLC is sized." }, { "from": 19, "to": 24, "label": "Traction", "description": "Preliminary efficacy and safety data are presented." }, { "from": 11, "to": 11, "label": "Competitive Analysis", "description": "NVL-520 is compared to existing treatments." } ], "loops": [ { "from": 7, "to": 12, "label": "Cost Of Inaction", "description": "What are the consequences of not addressing kinase resistance?" }, { "from": 19, "to": 24, "label": "Day In Life", "description": "How do patients benefit from Nuvalent's therapies?" }, { "from": 6, "to": 9, "label": "Jobs To Be Done", "description": "What are the unmet needs in cancer treatment?" } ] }